{"image_path": "output_diagrams\\page_1.png"}
{"image_path": "output_diagrams\\page_2.png"}
{"image_path": "output_diagrams\\page_3.png"}
{"title": "NCCN Evidence Blocks Categories and Definitions", "blocks": [{"category": "Efficacy of Regimen/Agent", "values": [{"score": 5, "description": "Highly effective: Cure likely and often provides long-term survival advantage"}, {"score": 4, "description": "Very effective: Cure unlikely but sometimes provides long-term survival advantage"}, {"score": 3, "description": "Moderately effective: Modest impact on survival, but often provides control of disease"}, {"score": 2, "description": "Minimally effective: No, or unknown impact on survival, but sometimes provides control of disease"}, {"score": 1, "description": "Palliative: Provides symptomatic benefit only"}]}, {"category": "Safety of Regimen/Agent", "values": [{"score": 5, "description": "Usually no meaningful toxicity: Uncommon or minimal toxicities; no interference with activities of daily living (ADLs)"}, {"score": 4, "description": "Occasionally toxic: Rare significant toxicities or low-grade toxicities only; little interference with ADLs"}, {"score": 3, "description": "Mildly toxic: Mild toxicity that interferes with ADLs"}, {"score": 2, "description": "Moderately toxic: Significant toxicities often occur but life threatening/fatal toxicity is uncommon; interference with ADLs is frequent"}, {"score": 1, "description": "Highly toxic: Significant toxicities or life threatening/fatal toxicity occurs often; interference with ADLs is usual and severe"}], "note": "For significant chronic or long-term toxicities, score decreased by 1"}, {"category": "Quality of Evidence", "values": [{"score": 5, "description": "High quality: Multiple well-designed randomized trials and/or meta-analyses"}, {"score": 4, "description": "Good quality: One or more well-designed randomized trials"}, {"score": 3, "description": "Average quality: Low quality randomized trial(s) or well-designed non-randomized trial(s)"}, {"score": 2, "description": "Low quality: Case reports or extensive clinical experience"}, {"score": 1, "description": "Poor quality: Little or no evidence"}]}, {"category": "Consistency of Evidence", "values": [{"score": 5, "description": "Highly consistent: Multiple trials with similar outcomes"}, {"score": 4, "description": "Mainly consistent: Multiple trials with some variability in outcome"}, {"score": 3, "description": "May be consistent: Few trials or only trials with few patients, whether randomized or not, with some variability in outcome"}, {"score": 2, "description": "Inconsistent: Meaningful differences in direction of outcome between quality trials"}, {"score": 1, "description": "Anecdotal evidence only: Evidence in humans based upon anecdotal experience"}]}, {"category": "Affordability of Regimen/Agent", "values": [{"score": 5, "description": "Very inexpensive"}, {"score": 4, "description": "Inexpensive"}, {"score": 3, "description": "Moderately expensive"}, {"score": 2, "description": "Expensive"}, {"score": 1, "description": "Very expensive"}]}], "example": {"E": 4, "S": 4, "Q": 3, "C": 4, "A": 3}, "image_path": "output_diagrams\\page_4.png"}
{"title": "NCCN Guidelines for Ductal Carcinoma In Situ (DCIS)", "stages": [{"stage": "DCIS Tis, N0, M0", "details": {"Diagnosis": ["History and physical exam", "Diagnostic bilateral mammogram", "Pathology review", "Determination of tumor estrogen receptor (ER) status", "Genetic counseling for patients at risk of hereditary breast cancer", "Breast MRI as indicated"], "Workup": [], "Primary Treatment": {"Breast-conserving surgery (BCS) without lymph node surgery": {"subsequent steps": [{"option": "Whole breast radiation therapy (WBRT) (category 1) with or without boost to tumor bed", "link": "See Postsurgical Treatment (DCIS-2)"}, {"option": "Accelerated partial breast irradiation (APBI/ PBI)", "link": "See Postsurgical Treatment (DCIS-2)"}, {"option": "No radiation (RT) (category 2B)", "link": "See Postsurgical Treatment (DCIS-2)"}]}, "Total mastectomy with or without sentinel lymph node biopsy (SLNB) with reconstruction (optional)": {"link": "See Postsurgical Treatment (DCIS-2)"}}}}], "image_path": "output_diagrams\\page_5.png"}
{"title": "DCIS Post-Surgical Treatment and Surveillance/Follow-Up", "sections": [{"title": "Risk Reduction Therapy for Ipsilateral Breast Following BCS", "content": ["Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if:", {"subsections": ["Treated with BCS and RT (category 1)", "Treated with excision alone"]}, "Endocrine therapy:", {"subsections": ["Tamoxifen for premenopausal patients", "Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism"]}, "Risk reduction therapy for contralateral breast:", "Counseling regarding risk reduction"]}, {"title": "Surveillance/Follow-Up", "content": ["Interval history and physical exam every 6\u201312 mo for 5 y, then annually", "Mammogram every 12 mo (first mammogram 6\u201312 mo, after breast-conservation therapy, category 2B)"]}], "image_path": "output_diagrams\\page_6.png"}
{"title": "Invasive Breast Cancer Clinical Staging and Workup", "stages": [{"name": "Non-metastatic (M0) invasive breast cancer", "workup": ["History and physical exam", "Diagnostic bilateral mammogram", "Ultrasound as necessary", "Breast MRI (optional), with special consideration for mammographically occult tumors", "Pathology review", "Determination of tumor estrogen/progesterone receptor (ER/PR) status and HER2 status", "Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) at any age, or is a candidate for adjuvant olaparib", "Address fertility and sexual health concerns as appropriate", "Pregnancy test in all patients of childbearing potential", "Assess for distress", "Consider additional imaging studies only in the presence of symptoms and signs of metastatic disease"]}, {"name": "Clinical Stage", "stages": [{"category": "cT0, cN+, M0", "recommendation": "See NCCN Guidelines for Occult Primary"}, {"category": "cT1-T3, cN0, M0", "consideration": [{"condition": "Not considering preoperative systemic therapy", "recommendation": ["See BCS Followed by RT", "See Mastectomy Followed by RT"]}, {"condition": "Considering preoperative systemic therapy", "recommendation": "See Additional Workup Prior to Preoperative Systemic Therapy"}]}, {"category": "Stage IV (M1) or Recurrent disease", "recommendation": "See Workup for Recurrent or Stage IV (M1) Disease"}]}, {"name": "Clinical pathologic diagnosis of inflammatory breast cancer (IBC)", "recommendation": "See Workup for IBC"}], "image_path": "output_diagrams\\page_7.png"}
{"title": "Locoregional Treatment of CT1-3, cN0 or cN+; M0 Disease: Breast-Conserving Surgery (BCS) Followed by RT", "flowchart": {"BCS with surgical axillary staging (category 1) +/- oncoplastic reconstruction": {"Negative axillary nodes": {"RT after completion of BCS and axillary staging": ["WBRT + boost to tumor bed, consider comprehensive regional nodal irradiation (RNI) in patients with central/medial tumors, pT3 tumors, or pT2 tumors and one of the following high-risk features: grade 3, extensive lymphovascular invasion (LVI), or ER-negative", "Consider APBI/PBI in selected low-risk patients (category 1)", "Consider omitting breast irradiation in patients \u226570 y of age with ER-positive, cN0, pT1 tumors who receive adjuvant endocrine therapy (category 1)"]}, "1-3 positive axillary nodes": {"Meets ALL of the following criteria: cT1-T2, cN0, No preoperative chemotherapy, 1-2 positive sentinel lymph node (SLNs), WBRT planned": {"Yes to all": ["WBRT + boost (use of comprehensive RNI with or without intentional inclusion of axilla is at the discretion of the radiation oncologist) (category 1)"], "No": ["WBRT with inclusion of any portion of the undissected axilla at risk + boost to tumor bed (category 1), Strongly consider comprehensive RNI"]}}, "\u22654 positive axillary nodes": ["WBRT + boost to tumor bed (category 1) + comprehensive RNI with inclusion of any portion of the undissected axilla at risk (category 1)"]}}, "image_path": "output_diagrams\\page_8.png"}
{"title": "Locoregional Treatment of CT1-3, cN0 or cN+, M0 Disease: Mastectomy Followed by RT", "flowchart": {"Total mastectomy with surgical axillary staging (category 1) \u00b1 reconstruction": {"Negative axillary nodes and tumor \u22645 cm and margins \u22651 mm": "No RT", "Negative axillary nodes and tumor \u22645 cm and negative margins but <1 mm": "Consider RT to chest wall. For patients with additional high-risk features, consider addition of comprehensive RNI (including any portion of the undissected axilla at risk).", "Negative axillary nodes and tumor >5 cm": "Consider RT to chest wall \u00b1 comprehensive RNI (including any portion of the undissected axilla at risk).", "1-3 positive axillary nodes": "Strongly consider RT to chest wall \u00b1 comprehensive RNI (including any portion of the undissected axilla at risk).", "\u22654 positive axillary nodes": "RT to chest wall \u00b1 comprehensive RNI (including any portion of the undissected axilla at risk) (category 1).", "Margins positive": "Re-excision to negative margins is preferred. If not feasible, then strongly consider RT to chest wall \u00b1 comprehensive RNI (including any portion of the undissected axilla at risk)."}}, "image_path": "output_diagrams\\page_9.png"}
{"title": "NCCN Evidence Blocks for Invasive Breast Cancer", "diagram": {"nodes": [{"id": "histology", "label": "HISTOLOGY", "attributes": ["Ductal/NST", "Lobular", "Mixed", "Micropapillary", "Metaplastic"]}, {"id": "hr_status", "label": "HR STATUS", "attributes": ["ER-positive", "PR-positive"]}, {"id": "her2_status", "label": "HER2 STATUS", "attributes": ["HER2-positive", "HER2-negative"]}, {"id": "systemic_adjuvant_treatment", "label": "SYSTEMIC ADJUVANT TREATMENT", "attributes": []}], "edges": [{"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "HER2-positive", "comment": "See BINV-5"}, {"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "Postmenopausal", "comment": "See BINV-6"}, {"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "pT1-3 AND pN0", "comment": "See BINV-7"}, {"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "pT1-3 AND pN+", "comment": "See BINV-8"}, {"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "HER2-negative", "comment": "See BINV-9"}, {"from": "histology", "to": "systemic_adjuvant_treatment", "label": "Favorable histologic type", "comment": "See Favorable Histologies (BINV-11)"}, {"from": "hr_status", "to": "systemic_adjuvant_treatment", "label": "ER+ or PR+ or HER2-", "comment": "See BINV-10"}]}, "image_path": "output_diagrams\\page_10.png"}
{"title": "Systemic Adjuvant Treatment: HR-Positive HER2-Positive Disease", "flowchart": {"start": "pT1, pT2, or pT3; and pN0 or pN1mi (\u22642 mm axillary node metastasis)", "steps": [{"condition": "Tumor \u22640.5 cm", "outcome": "pN0", "nextSteps": [{"condition": "", "outcome": "Consider adjuvant endocrine therapy with adjuvant chemotherapy with trastuzumab (category 2B)"}]}, {"condition": "Tumor \u22640.5 cm", "outcome": "pN1mi", "nextSteps": [{"condition": "", "outcome": "Adjuvant endocrine therapy or (Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy)"}]}, {"condition": "Tumor 0.6\u20131.0 cm", "outcome": "pN0", "nextSteps": [{"condition": "", "outcome": "Adjuvant chemotherapy with trastuzumab and endocrine therapy"}]}, {"condition": "Tumor >1 cm", "outcome": "pN+ (\u22651 ipsilateral metastases >2 mm)", "nextSteps": [{"condition": "", "outcome": "Consider adjuvant chemotherapy with trastuzumab-containing regimen and endocrine therapy"}, {"condition": "", "outcome": "Adjuvant chemotherapy with trastuzumab and endocrine therapy, preferred regimen"}]}]}, "image_path": "output_diagrams\\page_11.png"}
{"title": "SYSTEMIC ADJUVANT TREATMENT: HR-POSITIVE - HER2-NEGATIVE DISEASE POSTMENOPAUSAL PATIENTS with pT1-3 AND pN0 or pN+ TUMORS", "nodes": [{"id": 1, "text": "Tumor \u22640.5 cm and pN0", "next": [2]}, {"id": 2, "text": "Consider adjuvant endocrine therapy (category 2B)", "next": []}, {"id": 3, "text": "Tumor >0.5 cm or pN1mi (\u22642 mm axillary node metastases) or pN1 (1-3 positive nodes)", "next": [4, 11]}, {"id": 4, "text": "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)", "next": [5, 6]}, {"id": 5, "text": "Not done", "next": [7, 8]}, {"id": 6, "text": "Done", "next": [9, 10]}, {"id": 7, "text": "Adjuvant endocrine therapy (category 1)", "next": []}, {"id": 8, "text": "Adjuvant chemotherapy followed by endocrine therapy (category 1) or Adjuvant endocrine therapy", "next": []}, {"id": 9, "text": "Recurrence score <26", "next": [7]}, {"id": 10, "text": "Recurrence score \u226526", "next": [8]}, {"id": 11, "text": "pN2/pN3 (\u22654 ipsilateral metastases >2 mm)", "next": [8]}], "image_path": "output_diagrams\\page_12.png"}
{"image_path": "output_diagrams\\page_13.png"}
{"title": "Systemic Adjuvant Treatment: HR-Positive, HER2-Negative Disease in Premenopausal Patients with pT1-3 and pN+ Tumors", "flowchart": {"start": "pN1mi (\u22642 mm axillary node metastasis) or pN1 (1-3 positive nodes) or pN2/pN3 (\u22654 ipsilateral metastases >2 mm)", "steps": [{"decision": "Assess to determine if candidate for chemotherapy", "branches": [{"condition": "Not a candidate for chemotherapy", "outcome": "Adjuvant endocrine therapy + ovarian suppression/ablation"}, {"condition": "If candidate for chemotherapy consider gene expression assay to assess prognosis", "branches": [{"condition": "Adjuvant chemotherapy followed by endocrine therapy", "subcondition": "Adjuvant endocrine therapy + ovarian suppression/ablation or Adjuvant chemotherapy followed by endocrine therapy (category 1)"}]}]}]}, "image_path": "output_diagrams\\page_14.png"}
{"title": "Systemic Adjuvant Treatment: HR-Negative - HER2-Positive Disease", "flowchart": {"pT1, pT2, or pT3; and pN0 or pN1mi (\u22642 mm axillary node metastasis)": {"Tumor \u22640.5 cm": {"pN0": "Consider adjuvant chemotherapy\u00aa,PP with trastuzumabbd,de,ee (category 2B)", "pN1mi": "Consider adjuvant chemotherapy\u00aa,PP with trastuzumabbd,de,ee"}, "Tumor 0.6-1.0 cm": {"pN0": "Consider adjuvant chemotherapy\u00aa,PP with trastuzumabbd,de,ee", "pN1mi": "Adjuvant chemotherapy\u00aa,PP with trastuzumabbf (category 1)"}, "Tumor >1 cm": {"pN0": "Adjuvant chemotherapy\u00aa,PP with trastuzumabbf (category 1) or Adjuvant chemotherapy\u00aa,PP with trastuzumabbf + pertuzumabbh (category 1, preferred)", "pN1mi": "Adjuvant chemotherapy\u00aa,PP with trastuzumabbf (category 1) or Adjuvant chemotherapy\u00aa,PP with trastuzumabbf + pertuzumabbh (category 1, preferred)"}}, "pN+ (\u22651 ipsilateral metastases >2 mm)": "See Follow-Up (BINV-17)"}, "image_path": "output_diagrams\\page_15.png"}
{"title": "Systemic Adjuvant Treatment: HR-Negative - HER2-Negative Disease", "flowchart": {"Tumor \u22640.5 cm": {"pN0": "No adjuvant therapy", "pN1mi": "Consider adjuvant chemotherapy"}, "Tumor 0.6\u20131.0 cm": {"pN0": "Consider adjuvant chemotherapy", "pN1mi": "Consider adjuvant chemotherapy"}, "Tumor >1 cm": {"pN0": "Adjuvant chemotherapy (category 1)", "pN1mi": "Adjuvant chemotherapy (category 1)"}, "pN+ (\u22651 ipsilateral metastases >2 mm)": "Adjuvant chemotherapy (category 1)"}, "image_path": "output_diagrams\\page_16.png"}
{"title": "SYSTEMIC ADJUVANT TREATMENT: FAVORABLE HISTOLOGIES", "steps": [{"PURE TUBULAR, PURE MUCINOUS, PURE CRIBRIFORM, ENCAPSULATED OR SOLID PAPILLARY CARCINOMA": {"ER-positive and/or PR-positive, HER2-negative": {"pT1, pT2, or pT3; and pN0 or pN1mi (\u22642 mm axillary node metastasis)": {"<1 cm": "Consider adjuvant endocrine therapy for risk reduction", "1-2.9 cm": "Consider adjuvant endocrine therapy", "\u22653 cm": "Adjuvant endocrine therapy"}, "pN+ (\u22651 ipsilateral metastasis >2 mm)": "Adjuvant endocrine therapy + adjuvant chemotherapy"}, "ER-negative and PR-negative, HER2-negative": "Limited available data support local therapy only with consideration for systemic/targeted therapies only in pN+ disease"}}, {"ADENOID CYSTIC AND OTHER SALIVARY CARCINOMAS, SECRETORY CARCINOMA, RARE LOW-GRADE FORMS OF METAPLASTIC CARCINOMAv": {"ER-positive and/or PR-positive, HER2-negative": {"pT1, pT2, or pT3; and pN0 or pN1mi (\u22642 mm axillary node metastasis)": {"<1 cm": "Consider adjuvant endocrine therapy for risk reduction", "1-2.9 cm": "Consider adjuvant endocrine therapy", "\u22653 cm": "Adjuvant endocrine therapy"}, "pN+ (\u22651 ipsilateral metastasis >2 mm)": "Adjuvant endocrine therapy + adjuvant chemotherapy"}, "ER-negative and PR-negative, HER2-negative": "Limited available data support local therapy only with consideration for systemic/targeted therapies only in pN+ disease"}}], "image_path": "output_diagrams\\page_17.png"}
{"title": "Workup Prior to Preoperative Systemic Therapy", "flowchart": [{"Clinical Stage": ["c2T2\u2020 or cN+ and M0 or", "cT1c, cN0 HER2-positive disease or", "cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1\u2020\u2021)"]}, {"Additional Workup": ["Axillary assessment with exam", "Consider ultrasound", "Percutaneous biopsy of suspicious nodes\u00a7\u00a7", "CBC", "Comprehensive metabolic panel, including liver function tests and alkaline phosphatase", "Additional tests to consider as clinically indicated", "Chest diagnostic CT \u00b1 contrast", "Abdominal \u00b1 pelvic diagnostic CT with contrast or MRI with contrast", "Bone scan or sodium fluoride PET/CT (category 2B)", "FDG PET/CT (useful in certain circumstances)\u00b6\u00b6", "Breast MRI\u00ba (optional), with special consideration for mammographic occult tumors, if not previously done"]}], "references": ["For operable breast cancers: See Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)", "For inoperable breast cancers: See Preoperative Systemic Therapy (BINV-15)"], "image_path": "output_diagrams\\page_18.png"}
{"title": "Operable Disease: Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy", "steps": [{"description": "Prior to preoperative systemic therapy, perform the following:", "tasks": ["Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed", "Axillary imaging with ultrasound or MRI (if not previously done)", "Biopsy + clip placement recommended if suspicious and/or clinically positive axillary lymph nodes, if not previously done"]}, {"description": "Preoperative systemic therapy based on HR and HER2 status ", "arrow": "next"}, {"description": "See Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy (BINV-14)", "link": "BINV-14"}], "image_path": "output_diagrams\\page_19.png"}
{"title": "Surgical Treatment and Adjuvant Therapy after Preoperative Systemic Treatment for Invasive Breast Cancer", "flowchart": {"BCS possible": {"surgical treatment": "BCS with surgical axillary staging (see BINV-D) \u00b1 oncoplastic reconstruction", "adjuvant therapy": [{"condition": "cN+ and ypN0", "therapy": ["Adjuvant RT to the whole breast \u00b1 boost to the tumor bed", "Comprehensive RNI with inclusion of any portion of the undissected axilla at risk"]}, {"condition": "Any ypN+", "therapy": ["Adjuvant RT to the whole breast \u00b1 boost to the tumor bed", "Comprehensive RNI with inclusion of any portion of the undissected axilla at risk"]}, {"condition": "Any cN0, ypN0", "therapy": ["Adjuvant RT to the whole breast \u00b1 boost to tumor bed"]}]}, "BCS not possible": {"surgical treatment": "Mastectomy and surgical axillary staging (see BINV-D) \u00b1 reconstruction (optional)", "adjuvant therapy": [{"condition": "cN+ and ypN0", "therapy": ["Adjuvant RT to the chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk"]}, {"condition": "Any ypN+", "therapy": ["RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk"]}, {"condition": "cN0, ypN0 if axilla was assessed by SLNB or axillary node dissection", "therapy": ["Adjuvant systemic therapy (see BINV-16) without adjuvant RT"]}]}}, "image_path": "output_diagrams\\page_20.png"}
{"title": "Invasive Breast Cancer: Preoperative Systemic Therapy and Subsequent Treatment", "flowchart": {"Preoperative systemic therapyqq": {"Response to preoperative systemic therapyvv and tumor is operable": {"Mastectomy and surgical axillary stagingj + reconstruction (optional)q or BCS with surgical axillary stagingj,zz & oncoplastic reconstructionm": {"Adjuvant systemic therapyxx (see BINV-16) and Adjuvant RToo to the whole breast or chest wall and comprehensive RT with inclusion of any portion of the undissected axilla at risk.": null}, "Response to preoperative systemic therapyvv and tumor is operable": {"Follow pathway above": null}}, "No response to preoperative systemic therapyvv and/or tumor remains inoperable": {"Consider additional systemic therapy and/or preoperative radiationo": {"Response to preoperative systemic therapyvv and tumor is operable": {"Follow pathway above": null}, "No response to preoperative systemic therapyvv and tumor is inoperable": {"Individualize treatment": null}}}}}, "image_path": "output_diagrams\\page_21.png"}
{"title": "Adjuvant Systemic Therapy After Preoperative Systemic Therapy", "nodes": [{"id": 1, "label": "Response/Pathologic Stage after Preoperative Therapy", "children": [{"id": 2, "label": "HR-positive / HER2-negative", "conditions": ["ypT0N0 or pCR", "ypT1-4, N0 or ypN\u22651"], "children": [{"id": 3, "label": "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score \u22653, and residual disease. Select patients may be eligible for adjuvant abemaciclib", "condition": "ypT0N0 or pCR  (SEE BINV-K for eligibility criteria)"}, {"id": 4, "label": "Complete up to 1 year of HER2-targeted therapy with trastuzumab (category 1) \u00b1 pertuzumab", "condition": "ypT1-4, N0 or ypN\u22651"}]}, {"id": 5, "label": "HR-negative / HER2-positive", "conditions": ["ypT0N0 or pCR", "ypT1-4, N0 or ypN\u22651"], "children": [{"id": 6, "label": "Ado-trastuzumab emtansine (category 1) alone for 14 cycles. If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) \u00b1 pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)", "condition": "ypT1-4, N0 or ypN\u22651"}, {"id": 7, "label": "Follow-Up - BINV-17", "condition": "See BINV-17"}]}, {"id": 8, "label": "HR-positive / HER2-positive", "conditions": ["ypT0N0 or pCR", "ypT1-4, N0 or ypN\u22651"], "children": [{"id": 9, "label": "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab \u00b1 pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)", "condition": "ypT0N0 or pCR"}, {"id": 10, "label": "For high-risk: Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) (SEE BINV-17 for eligibility criteria)", "condition": "ypT1-4, N0 or ypN\u22651"}]}, {"id": 11, "label": "HR-negative / HER2-negative", "conditions": ["ypT0N0 or pCR", "ypT1-4, N0 or ypN\u22651"], "children": [{"id": 12, "label": "Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively) or Adjuvant capecitabine (6-8 cycles)", "condition": "ypT0N0 or pCR"}, {"id": 13, "label": "Adjuvant olaparib for 1 year if germline BRCA1/2 mutation", "condition": "ypT1-4, N0 or ypN\u22651"}]}]}], "image_path": "output_diagrams\\page_22.png"}
{"image_path": "output_diagrams\\page_23.png"}
{"title": "Stage IV (M1) Disease Clinical Workup for Invasive Breast Cancer", "steps": ["History and physical exam", "Discuss goals of therapy, adopt shared decision-making, and document course of care", "CBC", "Comprehensive metabolic panel, including liver function tests and alkaline phosphatase", "Imaging for systemic staging: Chest diagnostic CT \u00b1 contrast, Abdominal \u00b1 pelvic diagnostic CT with contrast or MRI with contrast, Brain MRI with contrast if suspicious CNS symptoms, Spine MRI with contrast if back pain or symptoms of cord compression", "Bone scan or sodium fluoride PET/CT (category 2B)", "Useful in certain circumstances: FDG PET/CT (consider FES PET/CT for ER-positive disease), X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan", "Biomarker testing: Biopsy of at least first recurrence of disease (consider re-biopsy if progression), Evaluation of ER/PR and HER2 status", "Comprehensive germline and somatic profiling to identify candidates for additional targeted therapies", "Genetic counseling if patient is at risk for hereditary breast cancer", "Assess for distress"], "references": [{"text": "See Treatment of Local and Regional Recurrence (BINV-19) and Supportive Care", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf#page=13"}, {"text": "See Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) Disease (BINV-20) and Supportive Care", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf#page=14"}], "notes": ["For tools to aid optimal assessment and management of older adults, see NCCN Guidelines for Older Adult Oncology.", "See Principles of Biomarker Testing (BINV-A).", "For risk criteria, see NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic.", "See NCCN Guidelines for Distress Management."], "image_path": "output_diagrams\\page_24.png"}
{"title": "Treatment of Local and Regional Recurrence", "nodes": [{"id": "1", "label": "Local only recurrence", "children": [{"id": "1.1", "label": "Initial treatment with BCS + RT\u2070", "children": [{"id": "1.1.1", "label": "Total mastectomy + axillary lymph node staging if level I/II axillary dissection not previously doneIII,mmmm"}, {"id": "1.1.2", "label": "Consider systemic therapyPPP. See Adjuvant Endocrine Therapy (BINV-K), Preoperative/Adjuvant Chemotherapy (BINV-L), Systemic Therapy for ER- and/or PR-Positive Recurrent Unresectable (local or regional) or Stage IV (M1) Disease (BINV-P), Chemotherapy Regimens, for Recurrent Unresectable (local or regional) or Stage IV (M1) Disease (BINV-Q)"}]}, {"id": "1.2", "label": "Initial treatment with mastectomy + level I/II axillary dissection and prior RT", "children": [{"id": "1.2.1", "label": "Surgical resection if possiblennn,ooo"}]}, {"id": "1.3", "label": "Initial treatment with mastectomy and no prior RT", "children": [{"id": "1.3.1", "label": "Surgical resection if possibleNNN + RT\u2070,ooo"}]}]}, {"id": "2", "label": "Regional only or Local and regional recurrencekkk", "children": [{"id": "2.1", "label": "Axillary recurrence", "children": [{"id": "2.1.1", "label": "Surgical resection if possibleNNN + RT if possible\u2070,ooo"}]}, {"id": "2.2", "label": "Supraclavicular recurrence", "children": [{"id": "2.2.1", "label": "RT if possible\u2070,ooo"}]}, {"id": "2.3", "label": "Internal mammary node recurrence", "children": [{"id": "2.3.1", "label": "RT if possible\u2070,ooo"}]}]}], "image_path": "output_diagrams\\page_25.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "flowchart": {"Recurrent unresectable (local or regional) or stage IV (M1) disease": [{"Bone disease present": ["Add denosumab, zoledronic acid, or pamidronate", {"ER- and/or PR-positive; HER2-negative": "See BINV-21", "ER- and/or PR-positive; HER2-positive": "See BINV-23", "ER- and PR-negative; HER2-positive": "See BINV-25", "ER- and PR-negative; HER2-negative": "See BINV-26"}]}, {"Bone disease not present": {"ER- and/or PR-positive; HER2-negative": "See BINV-21", "ER- and/or PR-positive; HER2-positive": "See BINV-23", "ER- and PR-negative; HER2-positive": "See BINV-25", "ER- and PR-negative; HER2-negative": "See BINV-26"}}]}, "image_path": "output_diagrams\\page_26.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease: ER- And/or PR-Positive; HER2-Negative", "flowchart": {"nodes": [{"id": "visceral_crisis", "label": "Visceral crisis", "connections": [{"target": "initial_systemic_therapy", "label": "", "condition": ""}]}, {"id": "no_visceral_crisis_prior_endocrine", "label": "No visceral crisis and Prior endocrine therapy within 1 yr", "connections": [{"target": "premenopausal_ablation", "label": "", "condition": ""}, {"target": "postmenopausal_systemic", "label": "", "condition": ""}]}, {"id": "no_visceral_crisis_no_prior_endocrine", "label": "No visceral crisis and No prior endocrine therapy within 1 yr", "connections": [{"target": "premenopausal_ablation_or_modulators", "label": "", "condition": ""}, {"target": "postmenopausal_systemic", "label": "", "condition": ""}]}, {"id": "initial_systemic_therapy", "label": "Consider initial systemic therapy", "connections": [{"target": "progression", "label": "Continue therapy until progression or unacceptable toxicity", "condition": ""}]}, {"id": "premenopausal_ablation", "label": "Premenopausal: Ovarian ablation or suppression + systemic therapy", "connections": [{"target": "progression", "label": "Continue endocrine therapy until progression or unacceptable toxicity", "condition": ""}]}, {"id": "postmenopausal_systemic", "label": "Postmenopausal: Systemic therapy", "connections": [{"target": "progression", "label": "Continue endocrine therapy until progression or unacceptable toxicity", "condition": ""}]}, {"id": "premenopausal_ablation_or_modulators", "label": "Premenopausal: Ovarian ablation or suppression + systemic therapy or Selective ER modulators", "connections": [{"target": "progression", "label": "Continue endocrine therapy until progression or unacceptable toxicity", "condition": ""}]}, {"id": "progression", "label": "Progression", "connections": []}]}, "image_path": "output_diagrams\\page_27.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease: ER- and/or PR-Positive; HER2-Negative", "flowchart": {"start": "Progression or unacceptable toxicity on first-line endocrine therapy", "steps": [{"condition": "If not endocrine therapy refractory", "options": [{"action": "Alternate endocrine therapy \u00b1 targeted therapy", "details": "see second-line therapy options on BINV-7"}, {"action": "Systemic therapy", "details": "see Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease (BINV-Q)"}]}, {"condition": "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease", "action": "Systemic therapy", "details": "see Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease (BINV-Q)"}, {"condition": "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer", "details": "At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process."}, {"condition": "Consider no further cytotoxic therapy", "actions": [{"action": "Continue supportive care", "details": "See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care"}]}, {"condition": "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy", "action": "Alternate systemic therapy", "details": "see Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease (BINV-Q)"}]}, "image_path": "output_diagrams\\page_28.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease: ER- and/or PR-Positive; HER2-Positive", "steps": [{"description": "Systemic therapy + HER2-targeted therapy", "references": ["UUU", "VVV"]}, {"description": "or Endocrine therapy \u00b1 HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)", "references": ["AAA", "AA", "BBBB"]}, {"description": "Continue therapy until progression or unacceptable toxicity", "references": ["XXX"]}, {"description": "Progression", "references": ["see BINV-24"]}], "image_path": "output_diagrams\\page_29.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease: ER- and/or PR-Positive; HER2-Positive", "flowchart": [{"step": "Progression on first-line endocrine therapy", "next_steps": [{"step": "Consider alternate endocrine therapy, if not endocrine refractory + HER2-targeted therapy", "next_steps": [{"step": "No clinical benefit after up to 3 sequential endocrine therapy regimens + HER2-targeted therapy or symptomatic visceral disease", "next_steps": [{"step": "Systemic therapy + HER2-targeted therapy until progression"}]}]}]}, {"step": "Progression on systemic therapy + HER2-targeted therapy", "next_steps": [{"step": "Alternate systemic therapy + HER2-targeted therapy", "next_steps": [{"step": "Continue HER2-targeted therapy until progression"}]}]}, {"step": "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process."}, {"step": "Consider no further HER2-targeted therapy and continue supportive care"}], "image_path": "output_diagrams\\page_30.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "flowchart": [{"step": "Systemic therapy + HER2-targeted therapy", "next": "Continue therapy until progression or unacceptable toxicity"}, {"step": "Continue therapy until progression or unacceptable toxicity", "next": "Progression"}, {"step": "Progression", "next": ["Alternate systemic therapy + HER2-targeted therapy", {"condition": "At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.", "next": "Consider no further HER2-targeted therapy and continue supportive care"}]}], "notes": ["See Principles of Biomarker Testing (BINV-A).", "See Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease (BINV-Q).", "See Principles of Monitoring Metastatic Disease (BINV-T).", "The potential side effects of additional line of therapy may outweigh any clinical benefit in a patient who has a compromised performance status. Patient preference must be taken into account.", "Continue HER2-targeted therapy following progression on first-line HER2-targeted chemotherapy for metastatic breast cancer. The optimal duration of trastuzumab in patients with long-term control of disease is unknown."], "image_path": "output_diagrams\\page_31.png"}
{"title": "Systemic Treatment of Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease: ER- and/or PR-Negative; HER2-Negative", "steps": [{"description": "Systemic therapy uuu, ffff", "next": ["Continue therapy until progression xxx or unacceptable toxicity"]}, {"description": "Continue therapy until progression xxx or unacceptable toxicity", "next": ["Alternative systemic therapy uuu, dddd"]}, {"description": "Alternative systemic therapy uuu, dddd", "next": [{"condition": "At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.", "next": ["Consider no further cytotoxic therapy zzz and continue supportive care"]}]}, {"description": "Consider no further cytotoxic therapy zzz and continue supportive care", "references": ["See NCCN Guidelines for Palliative Care", "See NCCN Guidelines for Supportive Care"]}], "image_path": "output_diagrams\\page_32.png"}
{"title": "Principles of Biomarker Testing: HER2 Testing", "flowchart": {"HER2 testing by validated immunohistochemistry (IHC) assay": {"IHC 0, 1+": {"result": "HER2 (\u2212)"}, "IHC 2+": {"result": "Equivocal", "action": "Must reflex test with ISH (if same specimen), or order new test with IHC or dual probe ISH (if new specimen available)"}, "IHC 3+": {"result": "HER2 (+)"}}, "HER2 testing by validated dual-probe ISH assay": {"HER2-Negative": {"criteria": [{"group": "Group 5", "condition": "HER2/CEP17 ratio <2.0 AND average HER2 copy number <4.0 signals/cell"}, {"group": "Group 2", "condition": "HER2/CEP17 ratio \u22652.0 AND average HER2 copy number <4.0 signals/cell and concurrent IHC 0\u22121+ or 2+"}, {"group": "Group 3", "condition": "HER2/CEP17 ratio <2.0 AND average HER2 copy number \u22656.0 signals/cell and concurrent IHC 0\u22121+"}, {"group": "Group 4", "condition": "HER2/CEP17 ratio <2.0 AND average HER2 copy number \u22654.0 and <6.0 signals/cell and concurrent IHC 0\u22121+ or 2+"}]}, "HER2-Positive": {"criteria": [{"group": "Group 1", "condition": "HER2/CEP17 ratio \u22652.0 AND average HER2 copy number \u22654.0 signals/cell and concurrent IHC 3+"}, {"group": "Group 3", "condition": "HER2/CEP17 ratio <2.0 AND average HER2 copy number \u22656.0 signals/cell and concurrent IHC 2+ or 3+"}, {"group": "Group 4", "condition": "HER2/CEP17 ratio <2.0 AND average HER2 copy number \u22654.0 and <6.0 signals/cell and concurrent IHC 3+"}]}}, "HER2-Positive (Definitive)": [{"group": "Group 1", "condition": "HER2/CEP17 ratio \u22652.0 AND average HER2 copy number \u22654.0 signals/cell"}]}, "image_path": "output_diagrams\\page_33.png"}
{"title": "Summary of ER IHC Scoring/Interpretation and Correlation of ER and Histology: Highly Unusual Results", "sections": [{"heading": "Summary of ER IHC Scoring/Interpretation", "table": {"headers": ["Results (following ER testing by validated IHC assay)", "Interpretation/ Report As"], "rows": [{"Results (following ER testing by validated IHC assay)": "0% \u2013 <1% of nuclei stain", "Interpretation/ Report As": "ER-negative"}, {"Results (following ER testing by validated IHC assay)": "1%\u201310% of nuclei stain", "Interpretation/ Report As": "ER-low\u2013positive (with recommended comment)"}, {"Results (following ER testing by validated IHC assay)": ">10% of nuclei stain", "Interpretation/ Report As": "ER-positive"}]}}, {"heading": "Correlation of ER and Histology: Highly Unusual Results", "columns": [{"subheading": "Highly Unusual ER-Negative Results", "entries": ["Low-grade invasive carcinomas of no special type (also known as invasive lobular carcinoma)", "Neuroendocrine tumors (classic type)", "Oncocrine cribriform, or mucinous carcinomas", "Apocrine carcinomas and solid papillary carcinomas"]}, {"subheading": "Highly Unusual ER-Positive Results", "entries": ["Metaplastic carcinomas of all subtypes", "Adenoid cystic carcinomas and other salivary gland-like carcinomas of the breast", "Secretory carcinoma", "Carcinomas with apocrine differentiation"]}]}], "image_path": "output_diagrams\\page_34.png"}
{"image_path": "output_diagrams\\page_35.png"}
{"image_path": "output_diagrams\\page_36.png"}
{"title": "Considerations for Surgical Axillary Staging", "elements": [{"label": "No palpable lymph node at diagnosis or \u22642 suspicious lymph nodes on imaging or \u22642 positive lymph nodes confirmed by needle biopsy + clip placement", "type": "decision", "options": [{"label": "SLN mapping and excision", "type": "decision", "options": [{"label": "SLN not identified", "type": "process", "result": "Axillary dissection level I/II"}, {"label": "SLN negative", "type": "process", "result": "No further axillary surgery (category 1)"}, {"label": "SLN positive", "type": "decision", "options": [{"label": "Clinically suspicious (palpable) lymph nodes or \u22653 suspicious lymph nodes on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging", "type": "decision", "options": [{"label": "US-guided FNA or core biopsy + clip placement recommended", "type": "decision", "options": [{"label": "FNA or core biopsy negative", "type": "decision", "options": [{"label": "If no preoperative chemotherapy was given", "type": "process", "result": "Axillary dissection level I/II"}, {"label": "If preoperative chemotherapy was given", "type": "process", "result": "Axillary dissection level I/II"}]}, {"label": "FNA or core biopsy positive", "type": "process", "result": "Axillary dissection level I/II"}]}]}, {"label": "Breast-conserving surgery", "type": "decision", "options": [{"label": "Meets ALL of the following criteria: cT1-2, cN0, No preoperative chemotherapy, 1-2 positive SLNs, WBRT planned", "type": "process", "result": "No further axillary surgery"}, {"label": "Micro-metastases seen in SLN", "type": "process", "result": "No further axillary surgery"}]}, {"label": "Mastectomy", "type": "decision", "options": [{"label": "Meets ALL of the following criteria: cT1-2, cN0, No preoperative chemotherapy, 1-2 positive SLNs, Adjuvant RT planned with intentional inclusion of undissected axilla at risk", "type": "process", "result": "No further axillary surgery"}, {"label": "Does not meet above criteria", "type": "process", "result": "Axillary dissection level I/II"}]}]}]}]}], "image_path": "output_diagrams\\page_37.png"}
{"image_path": "output_diagrams\\page_38.png"}
{"image_path": "output_diagrams\\page_39.png"}
{"title": "Margin Status Recommendations After BCS for Invasive Cancers and DCIS", "table": {"headers": ["No ink on tumor", "2-mm margin", "No margin necessary"], "rows": [{"condition": "Invasive breast cancer", "no_ink_on_tumor": "X", "2_mm_margin": "", "no_margin_necessary": ""}, {"condition": "Invasive breast cancer + DCIS", "no_ink_on_tumor": "X", "2_mm_margin": "", "no_margin_necessary": ""}, {"condition": "Invasive breast cancer + extensive DCIS", "no_ink_on_tumor": "X", "2_mm_margin": "", "no_margin_necessary": ""}, {"condition": "Pure DCIS", "no_ink_on_tumor": "", "2_mm_margin": "X", "no_margin_necessary": ""}, {"condition": "DCIS with microinvasion", "no_ink_on_tumor": "", "2_mm_margin": "X", "no_margin_necessary": ""}, {"condition": "Pure LCIS* at surgical margin", "no_ink_on_tumor": "", "2_mm_margin": "", "no_margin_necessary": "X"}, {"condition": "Atypia at surgical margin", "no_ink_on_tumor": "", "2_mm_margin": "", "no_margin_necessary": "X"}]}, "image_path": "output_diagrams\\page_40.png"}
{"image_path": "output_diagrams\\page_41.png"}
{"title": "Principles of Breast Reconstruction Following Surgery", "components": [{"type": "decision", "text": "Carcinoma in situ or Invasive carcinoma", "options": [{"condition": "Breast-conserving surgery", "nextStep": {"type": "decision", "text": "Reconstruction options", "options": [{"condition": "No reconstruction required", "description": "If ratio of tumor to breast volume is small and minimal cosmetic deformity will result"}, {"condition": "Consider oncoplastic reduction or mastopexy and simultaneous or delayed contralateral matching procedure"}, {"condition": "Consider bilateral breast reduction if symptoms warrant breast reduction"}, {"condition": "Local tissue rearrangement", "details": "regional flap (LD, partial LD, TDAP)"}]}}, {"condition": "Mastectomy", "nextStep": {"type": "decision", "text": "Reconstruction consideration", "options": [{"condition": "History of RT or adjuvant RT needed", "nextStep": "See Reconstruction Based on Planned Adjuvant RT or See Reconstruction Based on History of RT"}, {"condition": "No history of RT or no adjuvant RT needed", "nextStep": "Implant, autologous, or combination reconstruction"}, {"condition": "Unknown RT history or need for RT", "nextStep": "See Reconstruction Based on Unknown History of RT or Unknown Need for Postmastectomy RT"}]}}, {"condition": "IBC", "nextStep": "Delayed reconstruction"}]}], "notes": ["For more information regarding the categories and definitions used for the NCCN Evidence Blocks, see page EB-1.", "All recommendations are category 2A unless otherwise indicated.", "See NCCN Guidelines for the management of patients with cancer in a clinical trial. Participation in clinical trials is especially encouraged."], "references": ["a. See General Principles of Breast Reconstruction (BINV-H 5).", "b. See Patient Factors Affecting Choice of Reconstruction (BINV-H 6).", "c. An evaluation of the likely cosmetic outcome of BCS should be performed prior to surgery. Oncoplastic techniques for breast conservation can extend breast-conserving surgical options in situations where resection by itself would likely yield an unacceptable cosmetic outcome.", "d. Consider staged partial mastectomy reconstruction (oncoplastic approaches) if preoperative margin status is unclear (lobular, multifocal/centric).", "e. As with any mastectomy, there is a risk of locoregional cancer recurrence, and evidence suggests skin-sparing or skin-and-nipple-sparing mastectomy is probably equivalent to standard mastectomy in this regard. Post-mastectomy RT should still be applied in cases treated by skin-sparing mastectomy following the same selection criteria as for standard mastectomy."], "image_path": "output_diagrams\\page_42.png"}
{"title": "Principles of Breast Reconstruction Following Surgery", "flowchart": {"Reconstruction Based on Planned Adjuvant RT": {"Implant-based reconstruction planned": {"2 stage: tissue expander followed by permanent implant (prepectoral, partial submuscular, or total submuscular tissue expander)": ["Expansion followed by exchange to implant prior to the initiation of RT", "Expansion followed by RT and delayed exchange to implant"], "1 stage: direct to implant": "Expansion followed by RT and delayed exchange to implant"}, "Autologous reconstruction planned": ["Immediate autologous reconstruction", "Delayed reconstruction after the completion of RT", "Place tissue expander at the time of surgery, followed by expansion, RT, and delayed autologous reconstruction"]}}, "image_path": "output_diagrams\\page_43.png"}
{"title": "Principles of Breast Reconstruction Following Surgery", "flowchart": {"nodes": [{"id": 1, "text": "Recurrent carcinoma after breast conservation including RT", "next": 3}, {"id": 2, "text": "Delayed reconstruction after mastectomy and RT", "next": 3}, {"id": 3, "text": "Assess soft tissue preoperatively and intraoperatively", "next": [4, 5]}, {"id": 4, "text": "Adequate", "next": [6, 7]}, {"id": 5, "text": "Inadequate", "next": 15}, {"id": 6, "text": "Autologous (preferred) or combination", "next": null}, {"id": 7, "text": "1 stage: direct to implant", "next": null}, {"id": 8, "text": "2 stage: tissue expander followed by implant", "next": null}, {"id": 9, "text": "Adequate", "next": [10, 11]}, {"id": 10, "text": "Autologous (preferred) or combination", "next": null}, {"id": 11, "text": "2 stage: tissue expander followed by implant or autologous tissue", "next": null}, {"id": 12, "text": "Inadequate", "next": null}, {"id": 13, "text": "Autologous (preferred) or combination", "next": null}], "edges": [{"from": 1, "to": 3}, {"from": 2, "to": 3}, {"from": 3, "to": 4, "condition": "Adequate"}, {"from": 3, "to": 5, "condition": "Inadequate"}, {"from": 4, "to": 6}, {"from": 4, "to": 7, "condition": "1 stage"}, {"from": 4, "to": 8, "condition": "2 stage"}, {"from": 9, "to": 10}, {"from": 9, "to": 11, "condition": "2 stage"}, {"from": 12, "to": 13}, {"from": 5, "to": 12, "condition": "Inadequate"}]}, "image_path": "output_diagrams\\page_44.png"}
{"title": "Principles of Breast Reconstruction Following Surgery", "flowchart": {"steps": [{"text": "Immediate placement of tissue expander at the time of mastectomy (prepectoral, partial submuscular, total submuscular tissue expander placement)\u2020", "options": [{"text": "Adjuvant chemotherapy planned", "next": {"text": "Tissue expansion during chemotherapy", "options": [{"text": "No RT planned \u2192 Exchange tissue expander to implant or Convert to autologous tissue reconstruction", "end": true}, {"text": "RT planned \u2192 Exchange tissue expander to permanent implant\u2020 (prior to initiation of RT or after RT) or Conversion to autologous tissue reconstruction after RT", "end": true}]}}, {"text": "No adjuvant chemotherapy planned", "options": [{"text": "No RT planned \u2192 Tissue expansion followed by exchange to permanent implant or autologous tissue reconstruction", "end": true}, {"text": "RT planned \u2192 Tissue expansion (prior to RT), followed by exchange to permanent implant\u2020 after RT (can be considered prior to RT if no delay to initiation of treatment) or Tissue expansion followed by RT, and conversion to autologous tissue reconstruction", "end": true}]}]}, {"text": "1 stage: direct to implant\u2020 or Immediate autologous reconstruction or latissimus dorsi with implant at time of mastectomy\u2020", "options": [{"text": "Consider revisional surgeries to the ipsilateral or contralateral breast after RT if needed", "end": true}]}, {"text": "Delayed reconstruction", "options": [{"text": "RT not required \u2192 Reconstruction with implant, autologous tissue, or a combination", "end": true}, {"text": "RT required \u2192 See Reconstruction Based on History of RT (BINV-H 3)", "end": true}]}]}, "image_path": "output_diagrams\\page_45.png"}
{"image_path": "output_diagrams\\page_46.png"}
{"image_path": "output_diagrams\\page_47.png"}
{"image_path": "output_diagrams\\page_48.png"}
{"image_path": "output_diagrams\\page_49.png"}
{"image_path": "output_diagrams\\page_50.png"}
{"title": "Principles of Radiation Therapy", "flowchart": {"Accelerated Partial Breast Irradiation (APBI)/Partial Breast Irradiation (PBI)": {"description": ["APBI/PBI offers comparable local control to WBRT in selected low-risk patients with early-stage breast cancer. However, the optimal external beam-APBI/PBI technique/fractionation for minimizing long-term cosmetic effects has not been determined.", "Patients are encouraged to participate in clinical trials.", "The NCCN Panel recommends APBI/PBI for any patient who is BRCA negative and meets the 2016 ASTRO criteria."], "2016 ASTRO criteria": {"Eligibility": ["Patients aged \u226550 years to be considered 'suitable' for APBI/PBI if:", ["Invasive ductal carcinoma measuring \u22642 cm (pT1 disease) with negative margin widths of \u22652 mm, no LVI, and ER-positive or"], ["Low/intermediate nuclear grade, screening-detected DCIS measuring size \u22642.5 cm with negative margin widths of \u22653 mm."]]}, "RT dosing:": {"Regimen": [{"dose": "30 Gy/5 fractions QOD (preferred)", "method": "External beam RT (EBRT)"}, {"dose": "40 Gy/15 fractions", "method": "EBRT"}, {"dose": "34 Gy/10 fractions BID", "method": "Balloon/Intertstitial"}, {"dose": "38.5 Gy/10 fractions BID", "method": "EBRT"}]}}}, "image_path": "output_diagrams\\page_51.png"}
{"image_path": "output_diagrams\\page_52.png"}
{"image_path": "output_diagrams\\page_53.png"}
{"title": "Adjuvant Endocrine Therapy for Invasive Breast Cancer", "steps": [{"condition": "Premenopausal at diagnosis", "options": [{"treatment": "Tamoxifen for 5 years (category 1) \u00b1 ovarian suppression or ablation (category 1)", "follow_up_after_5_years": ["Postmenopausal: Aromatase inhibitor for 5 years (category 1) or Consider tamoxifen for an additional 5 years to complete 10 years", "Premenopausal: Continue tamoxifen for an additional 5 years to complete 10 years or No further endocrine therapy"]}, {"treatment": "Aromatase inhibitor for 5 years + ovarian suppression or ablation (category 1)", "follow_up_after_5_years": ["Consider aromatase inhibitor for an additional 3\u20135 years"]}, {"treatment": ["Aromatase inhibitor for 5 years (category 1)", "Aromatase inhibitor for 2\u20133 years (category 1) or tamoxifen for 2\u20133 years"], "follow_up_after_5_years": ["Consider aromatase inhibitor for an additional 3\u20135 years"]}]}, {"condition": "Postmenopausal at diagnosis", "options": [{"treatment": "Aromatase inhibitor for 5 years (category 1)", "follow_up_after_5_years": ["Tamoxifen to complete 5 years of endocrine therapy (category 1) or Aromatase inhibitor to complete 5 years of endocrine therapy (category 1) or Up to 5 years of an aromatase inhibitor (category 2B)"]}, {"treatment": "Tamoxifen for 4.5\u20136 years", "follow_up_after_tamoxifen": ["Aromatase inhibitor for 5 years (category 1) or Consider tamoxifen for an additional 5 years to complete 10 years", "Aromatase inhibitor for up to 10 years"]}]}, {"condition": "Patients with a contraindication to aromatase inhibitors, who decline aromatase inhibitors, or who are intolerant to aromatase inhibitors", "options": [{"treatment": "Tamoxifen for 5 years (category 1)", "follow_up_after_5_years": ["Consider tamoxifen for up to 10 years"]}]}], "image_path": "output_diagrams\\page_54.png"}
{"image_path": "output_diagrams\\page_55.png"}
{"title": "EVIDENCE BLOCKS FOR PREOPERATIVE/ADJUVANT THERAPY FOR HER2-NEGATIVE DISEASE", "sections": [{"heading": "Preferred regimens", "entries": [{"treatment": "Dose-dense AC (doxorubicin/cyclophosphamide) followed or preceded by paclitaxel every 2 weeks", "neoadjuvant": true, "adjuvant": true}, {"treatment": "Dose-dense AC (doxorubicin/cyclophosphamide) followed or preceded by weekly paclitaxel", "neoadjuvant": true, "adjuvant": true}, {"treatment": "TC (docetaxel and cyclophosphamide)", "neoadjuvant": true, "adjuvant": true}, {"treatment": "Olaparib, if germline BRCA1/2 mutations", "neoadjuvant": false, "adjuvant": true}, {"treatment": "High-risk triple-negative breast cancer: Preoperative pembrolizumab/carboplatin/paclitaxel, followed by preoperative pembrolizumab/cyclophosphamide/doxorubicin or epirubicin", "neoadjuvant": true, "adjuvant": false}, {"treatment": "High-risk triple-negative breast cancer: Adjuvant pembrolizumab", "neoadjuvant": false, "adjuvant": true}, {"treatment": "If triple-negative breast cancer and residual disease after preoperative therapy with taxane-, alkylator-, and anthracycline-based chemotherapy: capecitabine", "neoadjuvant": false, "adjuvant": true}]}, {"heading": "Useful in certain circumstances", "entries": [{"treatment": "Dose-dense AC (doxorubicin/cyclophosphamide)", "neoadjuvant": true, "adjuvant": true}, {"treatment": "AC (doxorubicin/cyclophosphamide) every 3 weeks", "neoadjuvant": true, "adjuvant": true}, {"treatment": "CMF (cyclophosphamide/methotrexate/fluorouracil)", "neoadjuvant": true, "adjuvant": true}, {"treatment": "AC followed by weekly paclitaxel", "neoadjuvant": true, "adjuvant": true}, {"treatment": "Capecitabine (maintenance therapy for TNBC after adjuvant chemotherapy)", "neoadjuvant": false, "adjuvant": true}]}, {"heading": "Other recommended regimens", "entries": [{"treatment": "AC followed by docetaxel every 3 weeks", "neoadjuvant": true, "adjuvant": true}, {"treatment": "EC (epirubicin/cyclophosphamide)", "neoadjuvant": true, "adjuvant": true}, {"treatment": "TAC (docetaxel/doxorubicin/cyclophosphamide)", "neoadjuvant": true, "adjuvant": true}]}, {"heading": "", "entries": [{"treatment": "Select Patients With TNBC", "neoadjuvant": true, "adjuvant": false}, {"treatment": "Paclitaxel/carboplatin (various schedules)", "neoadjuvant": true, "adjuvant": false}, {"treatment": "Docetaxel/carboplatin (if preoperative setting only)", "neoadjuvant": true, "adjuvant": false}]}], "image_path": "output_diagrams\\page_56.png"}
{"image_path": "output_diagrams\\page_57.png"}
{"title": "EVIDENCE BLOCKS FOR PREOPERATIVE/ADJUVANT THERAPY FOR HER2-POSITIVE DISEASE", "data": [{"category": "Preferred regimens", "items": [{"regimen": "Paclitaxel/trastuzumab", "neoadjuvant": 4, "adjuvant": 4}, {"regimen": "TCH (docetaxel/carboplatin/trastuzumab)", "neoadjuvant": 4, "adjuvant": 4}, {"regimen": "TCHP (docetaxel/carboplatin/trastuzumab)/pertuzumab", "neoadjuvant": 4, "adjuvant": 4}]}, {"category": "If residual disease after preoperative therapy", "items": [{"regimen": "Ado-trastuzumab emtansine", "neoadjuvant": null, "adjuvant": 4}]}, {"category": "If no residual disease after preoperative therapy or no preoperative therapy", "items": [{"regimen": "Trastuzumab to complete 1 year of HER2 targeted therapy", "neoadjuvant": null, "adjuvant": 4}, {"regimen": "Trastuzumab/pertuzumab to complete 1 year of HER2 targeted therapy", "neoadjuvant": null, "adjuvant": 4}]}, {"category": "Useful in certain circumstances", "items": [{"regimen": "Docetaxel/cyclophosphamide/trastuzumab", "neoadjuvant": 2, "adjuant": 2}, {"regimen": "AC followed by T/trastuzumab (doxorubicin/cyclophosphamide followed by paclitaxel/trastuzumab)", "neoadjuvant": 4, "adjuvant": 4}, {"regimen": "Dose-dense AC followed by T/trastuzumab (doxorubicin/cyclophosphamide followed by paclitaxel/trastuzumab)", "neoadjuvant": 4, "adjuvant": 4}, {"regimen": "AC followed by T/trastuzumab/pertuzumab (doxorubicin/cyclophosphamide followed by paclitaxel plus trastuzumab/pertuzumab)", "neoadjuvant": 4, "adjuvant": 4}, {"regimen": "Neratinib (adjuvant setting)", "neoadjuvant": null, "adjuvant": 3}, {"regimen": "Paclitaxel/trastuzumab/pertuzumab", "neoadjuvant": 2, "adjuvant": null}, {"regimen": "Ado-trastuzumab emtansine (TDM-1) (adjuvant setting)", "neoadjuvant": null, "adjuvant": 4}]}, {"category": "Other recommended regimens", "items": [{"regimen": "AC followed by docetaxel/trastuzumab", "neoadjuvant": 2, "adjuvant": 2}, {"regimen": "AC followed by docetaxel/trastuzumab/pertuzumab", "neoadjuvant": 2, "adjuvant": 2}]}], "image_path": "output_diagrams\\page_58.png"}
{"image_path": "output_diagrams\\page_59.png"}
{"title": "DOSING: PREOPERATIVE/ADJUVANT THERAPY REGIMENS", "sections": [{"title": "HER2-Negative Preferred Regimens", "regimens": [{"title": "Dose-dense AC followed by paclitaxel", "details": ["Doxorubicin 60 mg/m\u00b2 IV Day 1", "Cyclophosphamide 600 mg/m\u00b2 IV Day 1", "Cycled every 14 days for 4 cycles.", "Followed by:", "Paclitaxel 175 mg/m\u00b2 by 3 h IV infusion day 1", "Cycled every 14 days for 4 cycles."]}, {"title": "Dose-dense AC followed by weekly paclitaxel", "details": ["Doxorubicin 60 mg/m\u00b2 IV Day 1", "Cyclophosphamide 600 mg/m\u00b2 IV Day 1", "Cycled every 14 days for 4 cycles.", "Followed by:", "Paclitaxel 80 mg/m\u00b2 by 1 h IV infusion weekly for 12 weeks."]}, {"title": "TC", "details": ["Docetaxel 75 mg/m\u00b2 IV day 1", "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "Cycled every 21 days for 4-6 cycles."]}, {"title": "Preoperative pembrolizumab + chemotherapy followed by adjuvant pembrolizumab", "details": ["Preoperative:", "Pembrolizumab 200 mg IV Day 1", "Paclitaxel 80 mg/m\u00b2 IV Days 1, 8, 15", "Carboplatin AUC 5 IV Day 1 or", "Carboplatin AUC 1.5 IV Days 1, 8, 15", "Cycled every 21 days x 4 cycles (cycles 1\u20134)", "Followed by:", "Pembrolizumab 200 mg IV Day 1", "Doxorubicin 60 mg/m\u00b2 IV Day 1 or Epirubicin 90 mg/m\u00b2 IV Day 1", "Cyclophosphamide 600 mg/m\u00b2 IV Day 1", "Cycled every 21 days x 4 cycles (cycles 5\u20138)", "Followed by:", "Adjuvant pembrolizumab 200 mg IV Day 1", "Cycled every 21 days x 9 cycles"]}, {"title": "Capecitabine", "details": ["1,000\u20131,250 mg/m\u00b2 PO twice daily on days 1\u201314", "Cycled every 21 days for 6\u20138 cycles"]}, {"title": "Olaparib", "details": ["300 mg PO twice daily", "Cycled every 28 days for 1 year"]}]}], "image_path": "output_diagrams\\page_60.png"}
{"image_path": "output_diagrams\\page_61.png"}
{"title": "Dosing: Preoperative/Adjuvant Therapy Regimens for HER2-Positive Invasive Breast Cancer", "sections": [{"regimen_name": "Paclitaxel + trastuzumab", "dosing_details": ["Paclitaxel 80 mg/m\u00b2 IV weekly for 12 weeks", {"within": ["Trastuzumab 4 mg/kg IV with first dose of paclitaxel"], "followed_by": ["Trastuzumab 2 mg/kg IV weekly to complete 1 year of treatment. As an alternative, trastuzumab 6 mg/kg IV every 21 days may be used following the completion of paclitaxel, and given to complete 1 year of trastuzumab treatment."]}]}, {"regimen_name": "TCH", "dosing_details": ["Docetaxel 75 mg/m\u00b2 IV day 1", "Carboplatin AUC 6 IV day 1", {"cycled": "every 21 days for 6 cycles", "with": ["Trastuzumab 4 mg/kg IV wk 1", {"followed_by": ["Trastuzumab 2 mg/kg IV for 17 wks", "Followed by:", "Trastuzumab 6 mg/kg IV cycled every 21 days to complete 1 year of therapy"]}, "OR", {"trastuzumab_alternative": ["Trastuzumab 8 mg/kg IV wk 1", "Followed by:", "Trastuzumab 6 mg/kg IV cycled every 21 days to complete 1 year of therapy"]}]}]}, {"regimen_name": "TCH + pertuzumab", "dosing_details": ["Docetaxel 75 mg/m\u00b2 IV day 1", "Carboplatin AUC 6 IV day 1", {"cycled": "every 21 days for 6 cycles", "with": ["Trastuzumab 8 mg/kg IV day 1", "Pertuzumab 840 mg IV day 1", {"followed_by": ["Trastuzumab 6 mg/kg IV on day 1", "Pertuzumab 420 mg IV on day 1 cycled every 21 days to complete 1 year of therapy"]}]}]}], "image_path": "output_diagrams\\page_62.png"}
{"title": "HER2-Positive Breast Cancer: Dosing for Preoperative/Adjuvant Therapy Regimens", "sections": [{"therapy": "AC followed by T + trastuzumab", "components": [{"medication": "Doxorubicin 60 mg/m\u00b2 IV day 1", "cycle": "Cycled every 14 days for 4 cycles"}, {"medication": "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "cycle": "Cycled every 14 days for 4 cycles"}, {"medication": "Paclitaxel 80 mg/m\u00b2 IV weekly", "cycle": "Weekly for 12 weeks"}, {"component": "Trastuzumab", "description": ["Trastuzumab 4 mg/kg IV with first dose of paclitaxel", "Trastuzumab 2 mg/kg IV weekly to complete 1 year of treatment"]}]}, {"therapy": "Dose-dense AC followed by paclitaxel + trastuzumab", "components": [{"medication": "Doxorubicin 60 mg/m\u00b2 IV day 1", "cycle": "Cycled every 14 days for 4 cycles"}, {"medication": "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "cycle": "Cycled every 14 days for 4 cycles"}, {"medication": "Paclitaxel 175 mg/m\u00b2 IV", "cycle": "Cycled every 14 days for 4 cycles"}, {"component": "Trastuzumab", "description": ["Trastuzumab 4 mg/kg IV with first dose of paclitaxel", "Trastuzumab 2 mg/kg IV weekly to complete 1 year of treatment"]}]}, {"therapy": "AC or Dose-Dense AC followed by T + trastuzumab + pertuzumab", "components": [{"medication": "Doxorubicin 60 mg/m\u00b2 IV day 1", "cycle": "Cycled every 21 days for 4 cycles or Dose-dense Cycled every 14 days for 4 cycles"}, {"medication": "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "cycle": "Cycled every 21 days for 4 cycles or Dose-dense Cycled every 14 days for 4 cycles"}, {"medication": "Paclitaxel 80 mg/m\u00b2 IV", "cycle": "Weekly for 12 weeks"}, {"component": "Trastuzumab", "description": "Trastuzumab 6 mg/kg IV day 1 Cycled every 21 days to complete 1 year of therapy"}, {"component": "Pertuzumab", "description": "Pertuzumab 420 mg IV day 1 Cycled every 21 days to complete 1 year of therapy"}]}, {"therapy": "Docetaxel/cyclophosphamide + trastuzumab", "components": [{"medication": "Docetaxel 75 mg/m\u00b2 IV day 1", "cycle": "Cycled every 21 days for 4 cycles"}, {"medication": "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "cycle": "Cycled every 21 days for 4 cycles"}, {"component": "Trastuzumab", "description": ["Trastuzumab 2 mg/kg IV weekly for 12 weeks", "Then Trastuzumab 6 mg/kg IV every 21 days to complete 1 year of therapy"]}]}], "image_path": "output_diagrams\\page_63.png"}
{"title": "Dosing: Preoperative/Adjuvant Therapy Regimens for Invasive Breast Cancer", "sections": [{"title": "HER2-Positive (m,n,o", "subtitle": "Other Recommended Regimens", "regimens": [{"name": "AC followed by docetaxel + trastuzumab", "steps": ["Doxorubicin 60 mg/m\u00b2 IV day 1", "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "Cycling: Every 21 days for 4 cycles", {"followed by": ["Docetaxel 100 mg/m\u00b2 IV day 1", "Cycling: Every 21 days for 4 cycles"]}, {"with": ["Trastuzumab", "4 mg/kg IV wk 1; Followed by 2 mg/kg IV weekly for 11 wks; Followed by 6 mg/kg IV", "Cycling: Every 21 days to complete 1 yr of trastuzumab therapy"]}]}, {"name": "AC followed by docetaxel + trastuzumab + pertuzumab", "steps": ["Doxorubicin 60 mg/m\u00b2 IV day 1", "Cyclophosphamide 600 mg/m\u00b2 IV day 1", "Cycling: Every 21 days for 4 cycles", {"followed by": ["Pertuzumab 840 mg IV day 1 followed by 420 mg IV", "Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV", "Docetaxel 75\u2013100 mg/m\u00b2 IV day 1", "Cycling: Every 21 days for 4 cycles"]}, {"followed by": ["Trastuzumab 6 mg/kg IV", "Pertuzumab 420 mg IV day 1", "Cycling: Every 21 days to complete 1 yr of therapy"]}]}]}, {"title": "HER2-Positive (m,n,o", "subtitle": "Useful in Certain Circumstances", "regimens": [{"name": "Neratinib", "steps": ["120 mg PO daily on days 1\u20137", {"followed by": ["160 mg PO daily on days 8\u201314", {"followed by": ["240 mg PO daily on days 15\u201328", "Cycling: Every 28 days x 1 cycle"]}]}, {"followed by": ["240 mg PO daily on days 1\u201328", "Cycling: Every 28 days x 12 cycles beginning with cycle 2"]}]}, {"name": "Paclitaxel + trastuzumab + pertuzumab", "steps": ["Paclitaxel 80 mg/m\u00b2 IV day 1", "Cycling: Every 7 days x 12 cycles", "Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV", "Pertuzumab 840 mg IV day 1 followed by 420 mg IV", "Cycling: Every 21 days x 4 cycles", {"followed by": ["Trastuzumab 6 mg/kg IV", "Pertuzumab 420 mg IV day 1", "Cycling: Every 21 days to complete 1 yr of therapy"]}]}, {"name": "Ado-trastuzumab emtansine (T-DM1)", "steps": ["3.6 mg/kg IV day 1", "Cycling: Every 21 days for 17 cycles"]}]}], "image_path": "output_diagrams\\page_64.png"}
{"image_path": "output_diagrams\\page_65.png"}
{"image_path": "output_diagrams\\page_66.png"}
{"image_path": "output_diagrams\\page_67.png"}
{"title": "Gene Expression Assays for Consideration of Adjuvant Systemic Therapy", "diagram": [{"Assay": "21-gene (Oncotype Dx) (for pN0)", "Predictive": "Yes", "Prognostic": "Yes", "NCCN Category of Preference": "Preferred", "NCCN Category of Evidence and Consensus": "1", "Recurrence Risk and Treatment Implications": "BINV-N (2)"}, {"Assay": "21-gene (Oncotype Dx) for pN1 (1-3 positive nodes)", "Predictive": "Yes", "Prognostic": "Yes", "NCCN Category of Preference": "Postmenopausal: Preferred", "NCCN Category of Evidence and Consensus": "1", "Recurrence Risk and Treatment Implications": "BINV-N (2)"}, {"Assay": "21-gene (Oncotype Dx) for pN1 (1-3 positive nodes)", "Predictive": "Yes", "Prognostic": "Yes", "NCCN Category of Preference": "Premenopausal: Other", "NCCN Category of Evidence and Consensus": "2A", "Recurrence Risk and Treatment Implications": "BINV-N (2)"}, {"Assay": "70-gene (MammaPrint) for pN0 and pN1 (1-3 positive nodes)", "Predictive": "Not determined", "Prognostic": "Yes", "NCCN Category of Preference": "Other", "NCCN Category of Evidence and Consensus": "1", "Recurrence Risk and Treatment Implications": "BINV-N (3)"}, {"Assay": "50-gene (Prosigna) for pN0 and pN1 (1-3 positive nodes)", "Predictive": "Not determined", "Prognostic": "Yes", "NCCN Category of Preference": "Other", "NCCN Category of Evidence and Consensus": "2A", "Recurrence Risk and Treatment Implications": "BINV-N (3)"}, {"Assay": "12-gene (EndoPredict) for pN0 and pN1 (1-3 positive nodes)", "Predictive": "Not determined", "Prognostic": "Yes", "NCCN Category of Preference": "Other", "NCCN Category of Evidence and Consensus": "2A", "Recurrence Risk and Treatment Implications": "BINV-N (3)"}, {"Assay": "Breast Cancer Index (BCI)", "Predictive": "Predictive of benefit of extended adjuvant endocrine therapy", "Prognostic": "Yes", "NCCN Category of Preference": "Other", "NCCN Category of Evidence and Consensus": "2A", "Recurrence Risk and Treatment Implications": "BINV-N (4)"}], "image_path": "output_diagrams\\page_68.png"}
{"title": "Gene Expression Assays for Consideration of Adjuvant Systemic Therapy", "flowchart": [{"Assay": "21-gene (Oncotype Dx) (for postmenopausal patients with pN0 and pN1 [1\u20133 positive nodes])", "Recurrence Risk": "<26", "Treatment Implications": ["Patients with T1b/c\u20132, pN0, HR-positive, HER2-negative tumors, with risk scores (RS) between 0\u201310 have a risk of distant recurrence of <4%, and those with RS 11\u201325 derived no benefit from the addition of chemotherapy to endocrine therapy in the prospective TAILORx study.", "Postmenopausal patients with pT1\u20133, pN1, HR-positive, HER2-negative, with RS <26 derived no benefit from the addition of chemotherapy to endocrine therapy in the prospective RxPONDER study."]}, {"Assay": "21-gene (Oncotype Dx) (for postmenopausal patients with pN0 and pN1 [1\u20133 positive nodes])", "Recurrence Risk": "\u226526", "Treatment Implications": "In postmenopausal patients with pT1\u20133, HR-positive, HER2-negative, and pN0 and pN1 (1\u20133 positive nodes) tumors and an RS \u226526, the addition of chemotherapy to endocrine therapy is recommended."}, {"Assay": "21-gene (Oncotype Dx) (for premenopausal patients: pN0)", "Recurrence Risk": "\u226415", "Treatment Implications": "Premenopausal patients with T1b/c\u20132, pN0, HR-positive, HER2-negative tumors with RS \u226416 derived no benefit from the addition of chemotherapy to endocrine therapy in the prospective TAILORx study."}, {"Assay": "21-gene (Oncotype Dx) (for premenopausal patients: pN0)", "Recurrence Risk": "16-25", "Treatment Implications": "In premenopausal patients with RS between 16\u201325, a small benefit from the addition of chemotherapy could not be ruled out, but it is unclear if the benefit was due to the ovarian suppression effect promoted by chemotherapy in premenopausal patients. For this group, consider chemotherapy followed by endocrine therapy or alternatively, ovarian function suppression combined with either tamoxifen or an AI."}, {"Assay": "21-gene (Oncotype Dx) (for premenopausal patients: pN0)", "Recurrence Risk": "\u226526", "Treatment Implications": "In premenopausal patients with HR-positive, HER2-negative, and pN0 tumors and an RS \u226526, the addition of chemotherapy to endocrine therapy is recommended."}, {"Assay": "21-gene (Oncotype Dx) (for premenopausal patients with 1\u20133 positive nodes)", "Recurrence Risk": "<26", "Treatment Implications": ["In premenopausal patients with pT1\u20133 and pN1 (1\u20133 positive nodes) tumors and an RS <26, the addition of chemotherapy to endocrine therapy was associated with a lower rate of distant recurrence compared with endocrine monotherapy but it is unclear if the benefit was due to the ovarian suppression effects promoted by chemotherapy. For this group of patients, consider chemotherapy followed by endocrine therapy or alternatively, ovarian function suppression combined with either tamoxifen or an AI."]}, {"Assay": "21-gene (Oncotype Dx) (for premenopausal patients with 1\u20133 positive nodes)", "Recurrence Risk": "\u226526", "Treatment Implications": "In premenopausal patients with HR-positive, HER2-negative, pT1\u20133 and pN1 (1\u20133 positive nodes) tumors and an RS \u226526, the addition of chemotherapy to endocrine therapy is recommended."}], "image_path": "output_diagrams\\page_69.png"}
{"image_path": "output_diagrams\\page_70.png"}
{"title": "Gene Expression Assays for Consideration of Extended Adjuvant Systemic Therapy", "content": [{"Assay": "Breast Cancer Index (BCI)", "Recurrence Risk/ Predictive Result": [{"BCI (H/I) Low": ["For patients with T1 and T2 HR-positive, HER2-negative, and pN0 tumors, a BCI (H/I) in the low-risk range (0\u20135), regardless of T size, places the tumor into the same prognostic category as T1a\u2013T1b, N0, M0.", "Patients with BCI (H/I) low demonstrated a lower risk of distant recurrence (compared to BCI (H/I) high) and no significant improvement in disease-free survival (DFS) or OS compared to the control arm in terms of extending endocrine therapy duration."]}, {"BCI (H/I) High": ["For patients with T1 HR-positive, HER2-negative, and pN0 tumors, a BCI (H/I) high (5.1\u201310) demonstrated significant rates of late distant recurrence.", "In secondary analyses of the MA.17, Trans-aTTom, and IDEAL trials, patients with HR-positive, T1\u2013T3, pN0 or pN+ who had a BCI (H/I) high demonstrated significant improvements in DFS when adjuvant endocrine therapy was extended, compared to the control arm.", "In contrast, BCI (H/I) low patients derived no benefit from extended adjuvant therapy."]}]}], "image_path": "output_diagrams\\page_71.png"}
{"image_path": "output_diagrams\\page_72.png"}
{"image_path": "output_diagrams\\page_73.png"}
{"title": "Systemic Therapy for ER- and/or PR-Positive Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "content": [{"category": "Premenopausal Receiving Ovarian Ablation or Suppression", "subcategories": [{"name": "HER2-Negative and Postmenopausal", "subcontent": [{"title": "Preferred Regimens - First-Line Therapy", "items": ["Aromatase inhibitor + CDK4/6 inhibitor", "Aromatase inhibitor + ribociclib (category 1)", "Aromatase inhibitor + abemaciclib", "Aromatase inhibitor + palbociclib", "Fulvestrant + CDK4/6 inhibitor", "Fulvestrant + ribociclib (category 1)", "Fulvestrant + abemaciclib (category 1)", "Fulvestrant + palbociclib"]}, {"title": "Second- and Subsequent-Line Therapy", "items": ["Fulvestrant + CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib if CDK4/6 inhibitor not previously used) (category 1)", "For PIK3CA-mutated tumors, see additional targeted therapy options, see BINV-Q (6)", "Everolimus + endocrine therapy (exemestane, fulvestrant, tamoxifen)"]}]}, {"name": "Other Recommended Regimens", "subcontent": [{"title": "First- and/or Subsequent-Line Therapy", "items": ["Selective ER down-regulator", "Fulvestrant", "For ESR1 mutated tumors, see BINV-Q (6)"]}, {"title": "Selective ER down-regulator/fulvestrant", "items": ["category 1) + non-steroidal aromatase inhibitor (anastrozole, letrozole) (category 1)", "Non-steroidal aromatase inhibitor", "Anastrozole", "Letrozole"]}, {"title": "Selective ER modulator", "items": ["Tamoxifen", "Steroidal aromatase inactivator", "Exemestane"]}]}, {"name": "Useful in Certain Circumstances", "subcontent": [{"title": "Subsequent-Line Therapy", "items": ["Megestrol acetate", "Ethinyl estradiol", "Estrogen", "Antiprogestin", "Additional targeted therapy options, see BINV-Q (6)"]}]}, {"name": "HER2-Positive and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression", "subcontent": [{"title": "", "items": ["Aromatase inhibitor + trastuzumab", "Aromatase inhibitor + lapatinib", "Aromatase inhibitor + lapatinib + trastuzumab", "Fulvestrant + trastuzumab", "Tamoxifen + trastuzumab"]}]}]}], "image_path": "output_diagrams\\page_74.png"}
{"title": "Evidence Blocks for Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease", "diagram": {"Preferred Regimens": {"First-line Therapy": ["Abemaciclib/aromatase inhibitor", "Palbociclib/aromatase inhibitor", "Ribociclib/aromatase inhibitor", "Abemaciclib/fulvestrant", "Palbociclib/fulvestrant", "Ribociclib/fulvestrant", "Exemestane/everolimus", "Fulvestrant/everolimus", "Tamoxifen/everolimus"], "Second- and Subsequent-Line Therapy": []}, "Other Recommended Regimens": {"First-line Therapy": ["Fulvestrant", "Anastrozole", "Anastrozole/fulvestrant", "Letrozole", "Letrozole/fulvestrant", "Tamoxifen", "Exemestane"], "Second- and/or Subsequent-Line Therapy": ["Fulvestrant", "Anastrozole", "Anastrozole/fulvestrant", "Letrozole", "Letrozole/fulvestrant", "Tamoxifen", "Exemestane"]}, "Useful in certain circumstances": {"Subsequent-line Therapy": ["Megestrol acetate", "Estradiol", "Abemaciclib"]}}, "image_path": "output_diagrams\\page_75.png"}
{"title": "HER2-Positive and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression Systemic Therapy for ER- and/or PR-Positive Recurrent or Stage IV (M1) Disease", "content": [{"therapy": "Aromatase inhibitor/trastuzumab", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Aromatase inhibitor/lapatinib", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Aromatase inhibitor/lapatinib/trastuzumab", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Fulvestrant/trastuzumab", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Fulvestrant", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Tamoxifen/trastuzumab", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}, {"therapy": "Tamoxifen", "values": "\u25a0 \u25a0 \u25a0 \u25a0 \u25a0"}], "image_path": "output_diagrams\\page_76.png"}
{"title": "Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "flowchart": {"HR-Positive and HER2-Negative with Visceral Crisis or Endocrine Refractory": {"First Line": {"No germline BRCA1/2 mutation": "Systemic chemotherapy", "Germline BRCA1/2 mutation": "PARPi (olaparib, talazoparib)"}, "Second Line": {"HER2 IHC 1+ or 2+/ISH negative": "Fam-trastuzumab deruxtecan-nxki", "Not a candidate for fam-trastuzumab deruxtecan-nxki": "Sacituzumab govitecan"}, "Third Line and beyond": {"Any": "Systemic chemotherapy", "Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)": "Targeted agents"}}}, "image_path": "output_diagrams\\page_77.png"}
{"title": "Evidence Blocks for HR-Positive and HER2-Negative with Visceral Crisis or Endocrine Refractory", "content": {"Regimen": [{"name": "Systemic chemotherapy", "reference": "See BINV-Q (EB-4) for Evidence Blocks"}, {"name": "Olaparib for gBRCA1/2 mutated tumors", "evidence": "EEEE"}, {"name": "Talazoparib for gBRCA1/2 mutated tumors", "evidence": "EEEE"}, {"name": "Fam-trastuzumab deruxtecan-nxki (for HER2 IHC 1+ or 2+/ISH negative)", "evidence": "EEEE"}, {"name": "Sacituzumab govitecan-hziy (for HR+/HER2- TNBC)", "evidence": "EEEQ"}, {"name": "Targeted agents", "reference": "See BINV-Q (6). See BINV-Q (EB-5) for Evidence Blocks"}]}, "image_path": "output_diagrams\\page_78.png"}
{"title": "Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "categories": [{"category": "HR-Negative and HER2-Negative (Triple-Negative Breast Cancer; TNBC)", "lines": [{"title": "First Line", "options": [{"subtype_biomarker": "PD-L1 CPS \u226510 regardless of germline BRCA mutation status", "regimen": "Pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin) (Category 1, preferred)"}, {"subtype_biomarker": "PD-L1 CPS <10 and no germline BRCA1/2 mutation", "regimen": "Systemic chemotherapy"}, {"subtype_biomarker": "PD-L1 CPS <10 and germline BRCA1/2 mutation", "regimen": ["PARPi (olaparib, talazoparib) (Category 1, preferred)", "Platinum (cisplatin or carboplatin) (Category 1, preferred)"]}]}, {"title": "Second Line", "options": [{"subtype_biomarker": "Germline BRCA1/2 mutation", "regimen": "PARPi (olaparib, talazoparib) (Category 1, preferred)"}, {"subtype_biomarker": "Any", "regimen": "Sacituzumab govitecan-hziy (Category 1, preferred)"}, {"subtype_biomarker": "No germline BRCA1/2 mutation and HER2 IHC 1+ or 2+/ISH negative", "regimen": "Fam-trastuzumab deruxtecan-nxki (Category 1, preferred)"}]}, {"title": "Third Line and beyond", "options": [{"subtype_biomarker": "Biomarker positive (ie, MSI-H, NTRK, RET, TMB-H)", "regimen": "Targeted agents"}, {"subtype_biomarker": "Any", "regimen": "Systemic chemotherapy"}]}]}], "image_path": "output_diagrams\\page_79.png"}
{"title": "Evidence Blocks for HR-Negative and HER2-Negative (Triple-Negative Breast Cancer; TNBC)", "diagram": {"categories": ["Regimens"], "blocks": [{"name": "Olaparib for gBRCA1/2 mutated tumors", "properties": {"efficacy": 5, "safety": 4, "quality": 3, "consistency": 2, "affordability": 1}}, {"name": "Talazoparib for gBRCA1/2 mutated tumors", "properties": {"efficacy": 5, "safety": 4, "quality": 3, "consistency": 2, "affordability": 1}}, {"name": "Cisplatin (TNBC and germline BRCA 1/2)"}, {"name": "Carboplatin (TNBC and germline BRCA 1/2)"}, {"name": "Sacituzumab govitecan-hziy (for HR+/HER2- TNBC)", "properties": {"efficacy": 5, "safety": 4, "quality": 3, "consistency": 2, "affordability": 1}}, {"name": "Fam-trastuzumab deruxtecan-nxki (for HER2 IHC 1+ or 2+/ISH negative)"}, {"name": "Pembrolizumab + chemotherapy for TNBC"}, {"name": "Targeted agents", "links": [{"text": "See BINV-Q (EB-4) for Evidence Blocks", "url": "https://example.com/EB4"}]}, {"name": "Systemic chemotherapy", "links": [{"text": "See BINV-Q (EB-5) for Evidence Blocks", "url": "https://example.com/EB5"}]}]}, "image_path": "output_diagrams\\page_80.png"}
{"title": "Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "content": {"HR-Positive or -Negative and HER2-Positive": {"First Line": ["Pertuzumab + trastuzumab + docetaxel (Category 1, preferred)", "Pertuzumab + trastuzumab + paclitaxel (preferred)"], "Second Line": ["Fam-trastuzumab deruxtecan-nxki (Category 1, preferred)", "Tucatinib + trastuzumab + capecitabine (Category 1, preferred)", "Ado-trastuzumab emtansine (T-DM1)"], "Third Line": ["Trastuzumab + docetaxel or vinorelbine", "Trastuzumab + paclitaxel \u00b1 carboplatin", "Capecitabine + trastuzumab or lapatinib", "Trastuzumab + lapatinib (without cytotoxic therapy)", "Trastuzumab + other chemotherapy agents", "Neratinib + capecitabine"], "Fourth Line and Beyond (optimal sequence is not known)": ["Margetuximab-cmkb + chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)"]}}, "image_path": "output_diagrams\\page_81.png"}
{"title": "Evidence Blocks for Systemic Therapy Regimens for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease - HR-Positive or -Negative and HER2-Positive", "levels": {"first-line therapy": ["Pertuzumab/trastuzumab/docetaxel", "Pertuzumab/trastuzumab/paclitaxel"], "second-line therapy": ["Fam-trastuzumab deruxtecan-nxki"], "third-line therapy": ["Tucatinib/trastuzumab/capecitabine", "Ado-trastuzumab emtansine (T-DM1)"], "fourth-line and beyond": ["Trastuzumab/paclitaxel/carboplatin", "Trastuzumab/paclitaxel", "Trastuzumab/docetaxel", "Trastuzumab/vinorelbine", "Trastuzumab/capecitabine", "Lapatinib/capecitabine", "Trastuzumab/lapatinib (without cytotoxic therapy)", "Trastuzumab/other agents", "Neratinib/capecitabine", "Margetuximab-cmkb + chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine)"]}, "image_path": "output_diagrams\\page_82.png"}
{"image_path": "output_diagrams\\page_83.png"}
{"title": "Systemic Chemotherapy for HR-Positive or -Negative and HER2-Negative", "content": {"Preferred Regimens": ["Anthracyclines", "Doxorubicin", "Liposomal doxorubicin", "Taxanes", "Paclitaxel", "Anti-metabolites", "Capecitabine", "Gemcitabine", "Microtubule inhibitors", "Vinorelbine", "Eribulin"], "Other Recommended Regimens": ["Cyclophosphamide", "Docetaxel", "Albumin-bound paclitaxel", "Epirubicin", "Ixabepilone"], "Useful in Certain Circumstances": ["AC (doxorubicin/cyclophosphamide)", "EC (epirubicin/cyclophosphamide)", "CMF (cyclophosphamide/methotrexate/fluorouracil)", "Docetaxel/capecitabine", "GT (gemcitabine/paclitaxel)", "Gemcitabine/carboplatin", "Carboplatin + paclitaxel or albumin-bound paclitaxel"]}, "image_path": "output_diagrams\\page_84.png"}
{"title": "Evidence Blocks for Systemic Chemotherapy for HR-Positive or -Negative and HER2-Negative", "content": {"Preferred regimens": ["Doxorubicin", "Pegylated liposomal doxorubicin", "Paclitaxel", "Capecitabine", "Gemcitabine", "Vinorelbine", "Eribulin"], "Other recommended regimens": ["Cyclophosphamide", "Docetaxel", "Albumin-bound paclitaxel", "Epirubicin", "Ixabepilone"], "Useful in certain circumstances": ["AC (doxorubicin/cyclophosphamide)", "EC (epirubicin/cyclophosphamide)", "CMF (cyclophosphamide/methotrexate/fluorouracil)", "Docetaxel/capecitabine", "GT (gemcitabine/paclitaxel)", "Gemcitabine/carboplatin", "Carboplatin/paclitaxel", "Carboplatin/albumin-bound paclitaxel"]}, "image_path": "output_diagrams\\page_85.png"}
{"title": "Additional Targeted Therapies and Associated Biomarker Testing for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "flowchart": {"Biomarkers Associated with FDA-Approved Therapies": {"Breast Cancer Subtype": ["HR-positive/ HER2-negative", "HR-positive/ HER2-negative", "Any", "Any", "Any", "Any"], "Biomarker": ["PIK3CA activating mutation", "ESR1 mutation", "NTRK fusion", "MSI-H/dMMR", "TMB-H (\u226510 mut/mb)", "RET-fusion"], "Detection": ["PCR (blood or tissue block if blood negative)", "NGS, PCR (blood)", "FISH, NGS, PCR (tissue block)", "IHC, NGS, PCR (tissue block)", "NGS", "NGS"], "FDA-Approved Agents": ["Alpelisib + fulvestrant", "Elacestrant", "Larotrectinib, Entrectinib", "Pembrolizumab, Dostarlimab-gxly", "Pembrolizumab", "Selpercatinib"], "NCCN Category of Evidence": ["Category 1", "Category 2A", "Category 2A", "Category 2A", "Category 2A", "Category 2A"], "NCCN Category of Preference": ["Preferred second- or subsequent-line therapy", "Other recommended regimen", "", "Useful in certain circumstances", "", ""]}}, "image_path": "output_diagrams\\page_86.png"}
{"title": "Evidence Blocks for Additional Targeted Therapies and Associated Biomarker Testing for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "flowchart": {"Preferred regimens": ["Alpelisib + fulvestrant for tumors with PIK3CA mutation"], "Other recommended regimens": ["Elacestrant"], "Useful in certain circumstances": ["Larotrectinib (for tumors with NTRK fusion)", "Entrectinib (for tumors with NTRK fusion)", "Pembrolizumab (for MSI-H/dMMR)", "Dostarlimab-gxly (for MSI-H/dMMR)", "Pembrolizumab (for TMB-H)", "Selpercatinib"]}, "image_path": "output_diagrams\\page_87.png"}
{"title": "Emerging Biomarkers to Identify Novel Therapies for Patients with Stage IV (M1) Disease", "diagram": {"Breast Cancer Subtype": ["ER+/HER2-, ER-/HER2-", "Any", "Any"], "Emerging Biomarkers": ["HER2 activating mutations", "Somatic BRCA1/2 mutations", "Germline PALB2"], "Detection": ["NGS", "NGS", "Germline sequencing"], "Potential Targeted Therapy": ["Neratinib + fulvestrant, Neratinib \u00b1 trastuzumab/fulvestrant", "Olaparib", "Olaparib"], "NCCN Category of Evidence": ["Category 2B", "Category 2B", "Category 2B"], "NCCN Category of Preference": ["Useful in certain circumstances if ER+/HER2-, in patients who have already received CDK4/6 inhibitor therapy.", "Useful in certain circumstances", "Useful in certain circumstances"]}, "image_path": "output_diagrams\\page_88.png"}
{"image_path": "output_diagrams\\page_89.png"}
{"image_path": "output_diagrams\\page_90.png"}
{"title": "Systemic Therapy Regimens for Recurrent Unresectable Invasive Breast Cancer", "regimens": [{"name": "Trastuzumab + vinorelbine", "details": ["Vinorelbine 25 mg/m\u00b2 IV day 1 weekly; or 20\u201335 mg/m\u00b2 IV days 1 and 8; cycled every 21 days; or 25\u201330 mg/m\u00b2 IV days 1, 8, and 15; cycled every 28 days", "Trastuzumab 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly; or Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV day 1 every 21 days"]}, {"name": "Trastuzumab + capecitabine", "details": ["Capecitabine 1000\u20131250 mg/m\u00b2 PO twice daily days 1\u201314 cycled every 21 days", "Trastuzumab 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly; or Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV day 1 every 21 days"]}, {"name": "Lapatinib + capecitabine", "details": ["Lapatinib 1250 mg PO daily days 1\u201321", "Capecitabine 1000 mg/m\u00b2 PO twice daily days 1\u201314", "Cycled every 21 days"]}, {"name": "Trastuzumab + lapatinib", "details": ["Lapatinib 1000 mg PO daily for 21 days", "Trastuzumab 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly", "or", "Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV day 1 every 21 days"]}, {"name": "Neratinib + capecitabine", "details": ["Neratinib 240 mg PO daily on days 1\u201321; Capecitabine 750 mg/m\u00b2 PO twice daily on days 1\u201314; Cycled every 21 days", "or", "Neratinib 120 mg PO daily on days 1\u20137; followed by 160 mg PO daily on days 8\u201314; followed by 240 mg PO daily on days 15\u201321; Capecitabine 750 mg/m\u00b2 PO twice daily on days 1\u201314", "Cycled every 21 days x 1 cycle followed by Neratinib 240 mg PO daily on days 1 \u2013 21 and Capecitabine 750 mg/m\u00b2 PO twice daily on days 1\u201314; Cycled every 21 days beginning with cycle 2"]}, {"name": "Margetuximab-cmkb + capecitabine", "details": ["Margetuximab 15 mg/kg IV day 1", "Capecitabine 1000 mg/m\u00b2 PO twice daily days 1\u201314", "Cycled every 21 days"]}, {"name": "Margetuximab-cmkb + eribulin", "details": ["Margetuximab 15 mg/kg IV day 1", "Eribulin 1.4 mg/m\u00b2 IV days 1 and 8", "Cycled every 21 days"]}, {"name": "Margetuximab-cmkb + gemcitabine", "details": ["Margetuximab 15 mg/kg IV day 1", "Gemcitabine 1000 mg/m\u00b2 IV days 1 and 8", "Cycled every 21 days"]}, {"name": "Margetuximab-cmkb + vinorelbine", "details": ["Margetuximab 15 mg/kg IV day 1", "Vinorelbine 25\u201330 mg/m\u00b2 IV days 1 and 8", "Cycled every 21 days"]}], "image_path": "output_diagrams\\page_91.png"}
{"image_path": "output_diagrams\\page_92.png"}
{"image_path": "output_diagrams\\page_93.png"}
{"title": "Dosing: Additional Targeted Therapies and Associated Biomarker Testing for Recurrent Unresectable (Local or Regional) or Stage IV (M1) Disease", "content": [{"therapy": "Abemaciclib + fulvestrant", "dosing": ["Abemaciclib 300 mg PO daily on days 1\u201328; fulvestrant 500 mg IM on days 1 and 15", "28-day cycle for 1 cycle", "Followed by abemaciclib 300 mg PO daily on days 1\u201328; fulvestrant 500 mg IM on day 1", "Cycled every 28 days until disease progression or unacceptable toxicity"]}, {"therapy": "Dostarlimab-gxly", "dosing": ["500 mg IV on day 1", "Cycled every 21 days for cycles 1\u20134", "Followed by 1000 mg IV on day 1 of cycle 5", "Cycled every 42 days starting with cycle 5"]}, {"therapy": "Elacestrant", "dosing": ["345 mg PO daily on days 1-28", "Cycled every 28 days until disease progression or unacceptable toxicity"]}, {"therapy": "Entrectinib", "dosing": ["600 mg PO daily on days 1\u201328", "Cycled every 28 days until disease progression or unacceptable toxicity"]}, {"therapy": "Larotrectinib", "dosing": ["100 mg PO twice daily on days 1\u201328", "Cycled every 28 days until disease progression or unacceptable toxicity"]}, {"therapy": "Olaparib tablet", "dosing": ["300 mg PO twice daily", "Cycled every 28 days"]}, {"therapy": "Pembrolizumab", "dosing": ["200 mg IV on day 1, every 21 days until disease progression or unacceptable toxicity, OR up to 24 months", "400 mg IV on day 1, every 6 weeks until disease progression or unacceptable toxicity, OR up to 24 months"]}, {"therapy": "Pembrolizumab + chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin)", "dosing": ["Pembrolizumab 200 mg IV day 1 (given every 21 days)", "Albumin-bound paclitaxel 100 mg/m2 days 1, 8, 15 (given every 28 days) OR", "Paclitaxel 90 mg/m2 IV days 1, 8, 15 (given every 28 days) OR", "Pembrolizumab 200 mg IV day 1", "Gemcitabine 1000 mg/m2 IV days 1 and 8", "Carboplatin AUC 2 IV days 1 and 8", "Given every 21 days"]}, {"therapy": "Selpercatinib", "dosing": ["Patients \u226450kg: 120 mg PO twice daily until disease progression or unacceptable toxicity", "Patients >50kg: 160 mg PO twice daily until disease progression or unacceptable toxicity"]}, {"therapy": "Talazoparib 1mg tablet", "dosing": ["1 mg PO daily", "Cycled every 28 days"]}], "image_path": "output_diagrams\\page_94.png"}
{"image_path": "output_diagrams\\page_95.png"}
{"image_path": "output_diagrams\\page_96.png"}
{"image_path": "output_diagrams\\page_97.png"}
{"title": "Suggested Intervals of Follow-up for Patients with Metastatic Disease", "table": {"columns": ["Baseline Prior to New Therapy", "Chemotherapy", "Endocrine Therapy", "Restaging if Concern for Progression of Disease"], "rows": [{"type": "Symptom Assessment", "values": ["Yes", "Prior to each cycle", "Every 1-3 months", "Yes"]}, {"type": "Physical Examination", "values": ["Yes", "Prior to each cycle", "Every 1-3 months", "Yes"]}, {"type": "Performance Status", "values": ["Yes", "Prior to each cycle", "Every 1-3 months", "Yes"]}, {"type": "Weight", "values": ["Yes", "Prior to each cycle", "Every 1-3 months", "Yes"]}, {"type": "LFTs, CBC", "values": ["Yes", "Prior to each cycle, as indicated", "Every 1-3 months", "Yes"]}, {"type": "CT Chest/Abdomen/ Pelvis with Contrast", "values": ["Yes", "Every 2-4 cycles", "Every 2-6 months", "Yes"]}, {"type": "Bone Scan", "values": ["Yes", "Every 4-6 cycles", "Every 2-6 months", "Yes"]}, {"type": "PET/CT", "values": ["As clinically indicated", "As clinically indicated", "As clinically indicated", "As clinically indicated"]}, {"type": "Tumor Markers", "values": ["As clinically indicated", "As clinically indicated", "As clinically indicated", "As clinically indicated"]}]}, "image_path": "output_diagrams\\page_98.png"}
{"title": "NCCN Guidelines Version 4.2023 Phyllodes Tumor", "flowchart": {"Clinical Presentation": {"Clinical suspicion of phyllodes tumor:": ["Palpable mass", "Rapid growth", "Large size (>3 cm)", "Imaging with ultrasound suggestive of fibroadenoma except for size and/or history of growth"]}, "Workup": ["History and physical exam", "Ultrasound", "Mammogram for patients \u226530 y", {"Excisional biopsy": {"Findings": [{"Fibroadenoma": {"Treatment": "Observe", "Surveillance": null}}, {"Benign phyllodes tumor": {"Treatment": null, "Surveillance": "Clinical follow-up for 3 y"}}, {"Phyllodes tumor, borderline or malignant": {"Treatment": "Wide excision without axillary staging", "Surveillance": null}}, {"Invasive or in situ cancer": {"Treatment": "See appropriate guidelines", "Surveillance": null}}]}}, {"Core needle biopsy": {"Findings": [{"Indeterminate or benign phyllodes tumor": {"Treatment": "Excisional biopsy", "Surveillance": "See findings above"}}, {"Borderline or malignant phyllodes tumor": {"Treatment": "Wide excision without axillary staging", "Surveillance": "Clinical follow-up for 3 y"}}, {"Invasive or in situ cancer": {"Treatment": "See appropriate guidelines", "Surveillance": null}}]}}]}, "image_path": "output_diagrams\\page_99.png"}
{"title": "Phyllodes Tumor Recurrence", "flowchart": {"Locally recurrent breast mass following excision of phyllodes tumor": {"Workup": ["History and physical exam", "Ultrasound", "Mammogram", "Tissue sampling (histology preferred)", "Consider chest imaging (x-ray or CT, CT contrast optional)"], "Findings": {"No metastatic disease": {"Treatment": ["Re-excision with wide margins without axillary staging", "Consider post-operative radiation (category 2B)"]}, "Metastatic disease": {"Treatment": ["Metastatic disease management following principles of soft tissue sarcoma (See NCCN Guidelines for Soft Tissue Sarcoma)"]}}}}, "image_path": "output_diagrams\\page_100.png"}
{"title": "Workup for Paget Disease", "nodes": [{"id": 1, "text": "Clinical suspicion of Paget disease", "type": "start"}, {"id": 2, "text": "Clinical breast exam\nDiagnostic bilateral mammogram, ultrasound as necessary", "type": "process"}, {"id": 3, "text": "Examination or imaging positive for breast lesion", "type": "decision", "next": "See PAGET-2"}, {"id": 4, "text": "Examination and imaging negative for breast lesion", "type": "decision"}], "edges": [{"from": 1, "to": 2}, {"from": 2, "to": 3}, {"from": 2, "to": 4}], "image_path": "output_diagrams\\page_101.png"}
{"title": "Paget Disease Management Based on NCCN Guidelines", "flowchart": {"workup": [{"condition": "Examination or imaging positive for breast lesion", "actions": ["Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC", {"condition": "Breast and NAC biopsy negative", "treatment": ["Clinical follow-up", "Re-biopsy if not healing"]}, {"condition": "Breast DCIS and NAC Paget", "treatment": ["See NCCN Guidelines for Noninvasive Breast Cancer for DCIS (DCIS-1)"]}, {"condition": "Breast invasive cancer and NAC Paget", "treatment": ["See NCCN Guidelines for Invasive Breast Cancer (BINV-1)"]}, {"condition": "Breast negative for cancer and positive NAC Paget", "actions": ["NAC biopsy positive for Paget", {"condition": "NAC biopsy positive for Paget", "treatment": ["Clinical follow-up", "Re-biopsy if not healing"]}, {"condition": "Consider breast MRI and tissue sampling", "treatment": ["Central lumpectomy including NAC with WBRT", "Total mastectomy \u00b1 SLNB with or without breast reconstruction", "Central lumpectomy including NAC \u00b1 SLNB without RT (category 2B)"]}]}]}, {"condition": "Examination and imaging negative for breast lesion", "actions": ["Full-thickness skin biopsy of involved NAC", {"condition": "NAC biopsy positive for Paget", "treatment": ["Clinical follow-up", "Re-biopsy if not healing"]}]}]}, "image_path": "output_diagrams\\page_102.png"}
{"title": "Breast Cancer During Pregnancy - NCCN Guidelines", "steps": [{"title": "Workup", "details": ["Chest x-ray (with abdominal shielding)", "Abdominal ultrasound if indicated to assess liver metastases", "Consider non-contrast MRI of spine if indicated to assess for bone metastases"]}, {"title": "Clinical Presentation", "details": [{"condition": "First trimester", "actions": [{"title": "Discuss termination: Non-therapeutic", "details": []}, {"title": "Continuing pregnancy", "details": ["Mastectomy + axillary staging"]}]}, {"condition": "Pregnant patient with confirmed breast cancer; No distant metastases on staging", "details": [{"condition": "Second trimester/ Early third trimester", "actions": [{"title": "Mastectomy or BCS + axillary staging", "details": []}, {"title": "or", "details": []}, {"title": "Preoperative chemotherapy, mastectomy, or BCS + axillary staging", "details": []}]}, {"condition": "Late third trimester", "actions": [{"title": "Mastectomy or BCS + axillary staging", "details": []}]}]}]}, {"title": "Primary Treatment", "details": ["Mastectomy + axillary staging", "Mastectomy or BCS + axillary staging", "Preoperative chemotherapy, mastectomy, or BCS + axillary staging"]}, {"title": "Adjuvant Treatment", "details": [{"condition": "Begin adjuvant chemotherapy in second trimester", "actions": ["Adjuvant RT postpartum", "Adjuvant endocrine therapy postpartum"]}, {"condition": "Adjuvant chemotherapy", "actions": ["Adjuvant RT postpartum", "Adjuvant endocrine therapy postpartum"]}]}], "image_path": "output_diagrams\\page_103.png"}
{"title": "Workup for Clinical Presentation of Inflammatory Breast Cancer", "steps": [{"description": "History and physical exam by multidisciplinary team", "actions": ["obtain medical photography"]}, {"description": "CBC", "actions": []}, {"description": "Comprehensive metabolic panel", "actions": ["including LFTs and alkaline phosphatase"]}, {"description": "Pathology review", "actions": []}, {"description": "Determination of tumor ER/PR status and HER2 status", "actions": []}, {"description": "Fertility counseling", "actions": ["if premenopausal"]}, {"description": "Genetic counseling", "actions": ["if patient is at risk for hereditary breast cancer"]}, {"description": "Imaging", "actions": ["Bilateral diagnostic mammogram, ultrasound as necessary", "Chest diagnostic CT contrast", "Abdominal \u00b1 pelvic diagnostic CT with contrast or MRI with contrast", "Bone scan or FDG PET/CT", "Breast MRI (optional)"]}], "references": ["See Preoperative/Adjuvant Therapy Regimens (BINV-L)", "See IBC-2"], "image_path": "output_diagrams\\page_104.png"}
{"title": "Response to Preoperative Therapy in Inflammatory Breast Cancer", "steps": [{"condition": "Response", "action": "Total mastectomy + level I/II axillary dissection + RT to chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk \u00b1 delayed breast reconstruction", "sub_actions": ["Complete planned chemotherapy regimen course if not completed preoperatively plus endocrine treatment if ER-positive and/or PR-positive (sequential chemotherapy followed by endocrine therapy).", "Complete up to one year of HER2-targeted therapy if HER2-positive (category 1). May be administered concurrently with RT and with endocrine therapy if indicated."]}, {"condition": "No response", "action": "Consider additional systemic chemotherapy and/or preoperative radiation.", "sub_actions": ["Patients may be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process."]}, {"condition": "Response", "action": "See above pathway"}, {"condition": "No response", "action": "Individualized treatment"}], "image_path": "output_diagrams\\page_105.png"}
{"image_path": "output_diagrams\\page_106.png"}
{"image_path": "output_diagrams\\page_107.png"}
{"title": "AJCC Anatomic Stage Groups", "stages": {"Stage 0": {"Tis": "N0", "M0": "M0"}, "Stage IA": {"T1": "N0", "M0": "M0"}, "Stage IB": {"T0": "N1mi", "M0": "M0", "T1": "N1mi"}, "Stage IIA": {"T0": "N1", "M0": "M0", "T1": "N1", "T2": "N0"}, "Stage IIB": {"T2": "N1", "M0": "M0", "T3": "N0"}, "Stage IIIA": {"T0": "N2", "M0": "M0", "T1": "N2", "T2": "N2", "T3": "N1"}, "Stage IIIB": {"T4": "N2", "M0": "M0"}, "Stage IIIC": {"Any T": "N3", "M0": "M0"}, "Stage IV": {"Any T": "Any N", "M1": "M1"}}, "notes": ["1. T1 includes T1mi.", "2. T0 and T1 tumors with nodal micrometastases (N1mi) are staged as Stage IB.", "3. T2, T3, and T4 tumors with nodal micrometastases (N1mi) are staged using the N1 category.", "4. M0 includes M0(i+).", "5. The designation pM0 is not valid; any M0 is clinical.", "6. If a patient presents with M1 disease prior to neoadjuvant systemic therapy, the stage is considered Stage IV and remains Stage IV regardless of response to neoadjuvant therapy.", "7. Stage designation may be changed if postsurgical imaging studies reveal the presence of distant metastases, provided the studies are performed within 4 months of diagnosis in the absence of disease progression, and provided the patient has not received neoadjuvant therapy.", "8. Staging following neoadjuvant therapy is designated with \"yc\" or \"yp\" prefix to the TNM Classification. There is no anatomic stage group assigned if there is a complete pathological response (pCR) to neoadjuvant therapy, for example, ypT0ypN0M0."], "image_path": "output_diagrams\\page_108.png"}
{"image_path": "output_diagrams\\page_109.png"}
{"image_path": "output_diagrams\\page_110.png"}
{"image_path": "output_diagrams\\page_111.png"}
{"image_path": "output_diagrams\\page_112.png"}
{"image_path": "output_diagrams\\page_113.png"}
{"image_path": "output_diagrams\\page_114.png"}
{"image_path": "output_diagrams\\page_115.png"}
{"title": "Pathological Prognostic Stage", "diagram": {"columns": ["TNM", "Grade", "HER2", "ER", "PR", "Stage"], "rows": [["T4 N0 M0", "G1", "Positive", "Positive", "Positive", "IIIA"], ["T4 N1* M0", "G1", "Positive", "Positive", "Negative", "IIIB"], ["T4 N2 M0", "G1", "Positive", "Negative", "Positive", "IIIA"], ["T4 N2 M0", "G1", "Positive", "Negative", "Negative", "IIIB"], ["Any T N3 M0", "G1", "Negative", "Positive", "Positive", "IIIB"], ["Any T N3 M0", "G1", "Negative", "Positive", "Negative", "IIIC"], ["T4 N0 M0", "G2", "Positive", "Positive", "Positive", "IIIA"], ["T4 N1* M0", "G2", "Positive", "Positive", "Negative", "IIIB"], ["T4 N2 M0", "G2", "Positive", "Negative", "Positive", "IIIA"], ["Any T N3 M0", "G2", "Positive", "Negative", "Negative", "IIIC"], ["T4 N0 M0", "G3", "Negative", "Positive", "Positive", "IIIA"], ["T4 N1* M0", "G3", "Negative", "Positive", "Negative", "IIIB"], ["T4 N2 M0", "G3", "Negative", "Negative", "Positive", "IIIA"], ["Any T N3 M0", "G3", "Negative", "Negative", "Negative", "IIIC"], ["Any T Any N Any M+", "Any", "Any", "Any", "Any", "IV"]]}, "image_path": "output_diagrams\\page_116.png"}
{"image_path": "output_diagrams\\page_117.png"}
{"title": "NCCN Categories of Evidence and Consensus and Preference", "NCCN Categories of Evidence and Consensus": [{"Category 1": "Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate."}, {"Category 2A": "Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate."}, {"Category 2B": "Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate."}, {"Category 3": "Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate."}], "All recommendations": "All recommendations are category 2A unless otherwise indicated.", "NCCN Categories of Preference": [{"Preferred intervention": "Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability."}, {"Other recommended intervention": "Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes."}, {"Useful in certain circumstances": "Other interventions that may be used for selected patient populations (defined with recommendation)."}], "All recommendations (Preference)": "All recommendations are considered appropriate.", "image_path": "output_diagrams\\page_118.png"}
{"image_path": "output_diagrams\\page_119.png"}
{"image_path": "output_diagrams\\page_120.png"}
{"image_path": "output_diagrams\\page_121.png"}
{"image_path": "output_diagrams\\page_122.png"}
{"image_path": "output_diagrams\\page_123.png"}
{"image_path": "output_diagrams\\page_124.png"}
{"image_path": "output_diagrams\\page_125.png"}
{"image_path": "output_diagrams\\page_126.png"}
{"image_path": "output_diagrams\\page_127.png"}
{"image_path": "output_diagrams\\page_128.png"}
{"image_path": "output_diagrams\\page_129.png"}
{"image_path": "output_diagrams\\page_130.png"}
{"image_path": "output_diagrams\\page_131.png"}
{"image_path": "output_diagrams\\page_132.png"}
{"image_path": "output_diagrams\\page_133.png"}
{"image_path": "output_diagrams\\page_134.png"}
{"image_path": "output_diagrams\\page_135.png"}
{"image_path": "output_diagrams\\page_136.png"}
{"image_path": "output_diagrams\\page_137.png"}
{"image_path": "output_diagrams\\page_138.png"}
{"image_path": "output_diagrams\\page_139.png"}
{"image_path": "output_diagrams\\page_140.png"}
{"image_path": "output_diagrams\\page_141.png"}
{"image_path": "output_diagrams\\page_142.png"}
{"image_path": "output_diagrams\\page_143.png"}
{"image_path": "output_diagrams\\page_144.png"}
{"image_path": "output_diagrams\\page_145.png"}
{"image_path": "output_diagrams\\page_146.png"}
{"image_path": "output_diagrams\\page_147.png"}
{"image_path": "output_diagrams\\page_148.png"}
{"image_path": "output_diagrams\\page_149.png"}
{"image_path": "output_diagrams\\page_150.png"}
{"image_path": "output_diagrams\\page_151.png"}
{"image_path": "output_diagrams\\page_152.png"}
{"image_path": "output_diagrams\\page_153.png"}
{"image_path": "output_diagrams\\page_154.png"}
{"image_path": "output_diagrams\\page_155.png"}
{"image_path": "output_diagrams\\page_156.png"}
{"image_path": "output_diagrams\\page_157.png"}
{"image_path": "output_diagrams\\page_158.png"}
{"image_path": "output_diagrams\\page_159.png"}
{"image_path": "output_diagrams\\page_160.png"}
{"image_path": "output_diagrams\\page_161.png"}
{"image_path": "output_diagrams\\page_162.png"}
{"image_path": "output_diagrams\\page_163.png"}
{"image_path": "output_diagrams\\page_164.png"}
{"image_path": "output_diagrams\\page_165.png"}
{"image_path": "output_diagrams\\page_166.png"}
{"image_path": "output_diagrams\\page_167.png"}
{"image_path": "output_diagrams\\page_168.png"}
{"image_path": "output_diagrams\\page_169.png"}
{"image_path": "output_diagrams\\page_170.png"}
{"image_path": "output_diagrams\\page_171.png"}
{"image_path": "output_diagrams\\page_172.png"}
{"image_path": "output_diagrams\\page_173.png"}
{"image_path": "output_diagrams\\page_174.png"}
{"image_path": "output_diagrams\\page_175.png"}
{"image_path": "output_diagrams\\page_176.png"}
{"image_path": "output_diagrams\\page_177.png"}
{"image_path": "output_diagrams\\page_178.png"}
{"image_path": "output_diagrams\\page_179.png"}
{"image_path": "output_diagrams\\page_180.png"}
{"image_path": "output_diagrams\\page_181.png"}
{"image_path": "output_diagrams\\page_182.png"}
{"image_path": "output_diagrams\\page_183.png"}
{"image_path": "output_diagrams\\page_184.png"}
{"image_path": "output_diagrams\\page_185.png"}
{"image_path": "output_diagrams\\page_186.png"}
{"image_path": "output_diagrams\\page_187.png"}
{"image_path": "output_diagrams\\page_188.png"}
{"image_path": "output_diagrams\\page_189.png"}
{"image_path": "output_diagrams\\page_190.png"}
{"image_path": "output_diagrams\\page_191.png"}
{"image_path": "output_diagrams\\page_192.png"}
{"image_path": "output_diagrams\\page_193.png"}
{"image_path": "output_diagrams\\page_194.png"}
{"image_path": "output_diagrams\\page_195.png"}
{"image_path": "output_diagrams\\page_196.png"}
{"image_path": "output_diagrams\\page_197.png"}
{"image_path": "output_diagrams\\page_198.png"}
{"image_path": "output_diagrams\\page_199.png"}
{"image_path": "output_diagrams\\page_200.png"}
{"image_path": "output_diagrams\\page_201.png"}
{"image_path": "output_diagrams\\page_202.png"}
{"image_path": "output_diagrams\\page_203.png"}
{"image_path": "output_diagrams\\page_204.png"}
{"image_path": "output_diagrams\\page_205.png"}
{"image_path": "output_diagrams\\page_206.png"}
{"image_path": "output_diagrams\\page_207.png"}
{"image_path": "output_diagrams\\page_208.png"}
{"image_path": "output_diagrams\\page_209.png"}
{"image_path": "output_diagrams\\page_210.png"}
{"image_path": "output_diagrams\\page_211.png"}
{"image_path": "output_diagrams\\page_212.png"}
{"image_path": "output_diagrams\\page_213.png"}
{"image_path": "output_diagrams\\page_214.png"}
{"image_path": "output_diagrams\\page_215.png"}
{"image_path": "output_diagrams\\page_216.png"}
{"image_path": "output_diagrams\\page_217.png"}
{"image_path": "output_diagrams\\page_218.png"}
{"image_path": "output_diagrams\\page_219.png"}
{"image_path": "output_diagrams\\page_220.png"}
{"image_path": "output_diagrams\\page_221.png"}
{"image_path": "output_diagrams\\page_222.png"}
{"image_path": "output_diagrams\\page_223.png"}
{"image_path": "output_diagrams\\page_224.png"}
{"image_path": "output_diagrams\\page_225.png"}
{"image_path": "output_diagrams\\page_226.png"}
{"image_path": "output_diagrams\\page_227.png"}
{"image_path": "output_diagrams\\page_228.png"}
{"image_path": "output_diagrams\\page_229.png"}
{"image_path": "output_diagrams\\page_230.png"}
{"image_path": "output_diagrams\\page_231.png"}
{"image_path": "output_diagrams\\page_232.png"}
{"image_path": "output_diagrams\\page_233.png"}
{"image_path": "output_diagrams\\page_234.png"}
{"image_path": "output_diagrams\\page_235.png"}
{"image_path": "output_diagrams\\page_236.png"}
{"image_path": "output_diagrams\\page_237.png"}
{"image_path": "output_diagrams\\page_238.png"}
{"image_path": "output_diagrams\\page_239.png"}
{"image_path": "output_diagrams\\page_240.png"}
{"image_path": "output_diagrams\\page_241.png"}
{"image_path": "output_diagrams\\page_242.png"}
{"image_path": "output_diagrams\\page_243.png"}
{"image_path": "output_diagrams\\page_244.png"}
{"image_path": "output_diagrams\\page_245.png"}
{"image_path": "output_diagrams\\page_246.png"}
{"image_path": "output_diagrams\\page_247.png"}
{"image_path": "output_diagrams\\page_248.png"}
{"image_path": "output_diagrams\\page_249.png"}
{"image_path": "output_diagrams\\page_250.png"}
{"image_path": "output_diagrams\\page_251.png"}
{"image_path": "output_diagrams\\page_252.png"}
{"image_path": "output_diagrams\\page_253.png"}
{"image_path": "output_diagrams\\page_254.png"}
{"image_path": "output_diagrams\\page_255.png"}
{"image_path": "output_diagrams\\page_256.png"}
{"image_path": "output_diagrams\\page_257.png"}
